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Lipid availability determines fate of skeletal 
progenitor cells via SOX9
Nick van Gastel1,2,3,4,5, Steve Stegen1,2, Guy Eelen6,7, Sandra Schoors6,7, Aurélie Carlier2,8,9,10, 
Veerle W. Daniëls11,12, Ninib Baryawno3,4,5,13, Dariusz Przybylski14, Maarten Depypere15,16,  
Pieter-Jan Stiers1,2, Dennis Lambrechts2,17,18, Riet Van Looveren1, Sophie Torrekens1,  
Azeem Sharda3,4,5, Patrizia Agostinis19, Diether Lambrechts20,21, Frederik Maes15,16,  
Johan V. Swinnen11, Liesbet Geris2,8,9, Hans Van Oosterwyck2,8, Bernard Thienpont20,21,  
Peter Carmeliet6,7, David T. Scadden3,4,5 & Geert Carmeliet1,2 ✉
The avascular nature of cartilage makes it a unique tissue1–4, but whether and how the 
absence of nutrient supply regulates chondrogenesis remain unknown. Here we show 
that obstruction of vascular invasion during bone healing favours chondrogenic over 
osteogenic differentiation of skeletal progenitor cells. Unexpectedly, this process is 
driven by a decreased availability of extracellular lipids. When lipids are scarce, 
skeletal progenitors activate forkhead box O (FOXO) transcription factors, which bind 
to the Sox9 promoter and increase its expression. Besides initiating chondrogenesis, 
SOX9 acts as a regulator of cellular metabolism by suppressing oxidation of fatty 
acids, and thus adapts the cells to an avascular life. Our results define lipid scarcity as 
an important determinant of chondrogenic commitment, reveal a role for FOXO 
transcription factors during lipid starvation, and identify SOX9 as a critical metabolic 
mediator. These data highlight the importance of the nutritional microenvironment 
in the specification of skeletal cell fate.
Bone repair reiterates the developmental endochondral ossification 
process and is initiated by periosteal skeletal progenitor cells that first 
form an avascular cartilage template which is later replaced by bone1,2. 
Among the factors involved in chondrogenesis, the transcription fac-
tor SOX9 has been the most extensively studied, but how it is induced 
in skeletal progenitor cells is poorly understood. Since cartilage is 
avascular, the absence of blood vessels itself has been suggested to 
initiate chondrogenesis3–6, but a causal link has not been confirmed 
and remains controversial7. In this study, we provide evidence that 
local blood vessel availability determines skeletal progenitor cell fate 
during bone healing through a multifaceted mechanism involving lipid 
metabolism, FOXO signalling and SOX9.
Vascularity controls skeletal cell fate
To investigate whether the absence of vasculature determines skel-
etal progenitor fate we transplanted viable (autologous) bone grafts 
into femoral defects in mice, inducing a periosteal-driven healing 
response8. Periosteal progenitor cells near the host-graft border 
formed cartilage, whereas cells in the centre differentiated directly 
into bone-forming osteoblasts (Extended Data Fig. 1a). Periosteal 
cells did not contribute to blood vessels in the callus (Fig. 1a), but 
actively promoted vascular ingrowth as their removal reduced bone 
formation and callus vascularization (Extended Data Fig. 1b–d). At 
post-fracture day (PFD) 7 the central periosteal callus vasculature 
was highly connected with that of the surrounding muscle (Fig. 1b), 
suggesting that periosteal cells attract blood vessels from this site. To 
investigate the importance of this vascular ingrowth for bone repair, 
we inserted polycarbonate filters with different pore sizes between 
graft and muscle (Fig. 1c). Inserting a 30-μm-pore filter still allowed 
capillaries to transverse the pores at PFD7, whereas a 0.2-μm-pore 
size prevented vascular ingrowth into the periosteal layer, as shown 
by the numerous capillaries adjacent to the filter on the muscle side 
and reduced callus vascularization (Fig. 1d). Concomitantly, periosteal 
cellularity decreased because of reduced proliferation and moderately 
increased cell death (Extended Data Fig. 2a, b), but more importantly, 
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the number of SOX9+ early chondrogenic cells was higher at the central 
graft region (Fig. 1e). This chondrogenic switch resulted in less bone 
(Extended Data Fig. 2c) but more type 2 collagen (COL2)+ cartilage 
matrix in the central region at PFD14 (Fig. 1f), where graft cells dif-
ferentiated to chondrocytes instead of osteoblasts (Extended Data 
Fig. 2d). At PFD28, successful healing was observed in both conditions, 
although the presence of small cartilage islands in the callus with filter 
(75.0 ± 14.4% of sections) suggests delayed healing (Extended Data 
Fig. 2e, f). Thus, skeletal progenitor cells undergo chondrogenic rather 
than osteogenic differentiation when blood supply is limited, securing 
successful bone healing.
During bone healing, the vasculature supplies nutrients (oxygen, 
glucose, amino acids and lipids), growth factors and perivascular 
progenitor cells9. To distinguish between these components, we 
applied a computational model of bone healing10,11 to our bone-
graft setup, in which cell fate and tissue formation are controlled 
by nutrient availability, osteochondrogenic growth factors, matrix 
density and local cell number (Extended Data Fig. 3a, b). The model 
correctly described the spatiotemporal progression of normal bone-
graft healing (that is, blood vessels can come from the muscle; com-
pare Extended Data Fig. 3b with Extended Data Fig. 1a). When the 
presence of a filter was mimicked by limiting diffusion of nutrients 
from the muscle side (20–40% of the nutrients normally supplied by 
the vasculature), the model recapitulated the chondrogenic switch 
in the central graft region (Extended Data Fig. 3c, d). An additional 
supply of growth factors and/or progenitor cells from the muscle 
side did not significantly affect this bone repair profile (Extended 
Data Fig. 3e). The in silico model thus supports the hypothesis that 
nutrients supplied by the vasculature regulate skeletal progenitor 
cell differentiation.
Lipid scarcity induces chondrogenesis
To test this hypothesis, we investigated the nutritional control of cell 
fate using two models of skeletal progenitors: the C3H10T1/2 cell line, 
a homogeneous population retaining multipotency properties12, and 
primary murine periosteal cells, which are more heterogeneous but 
contain true skeletal stem and progenitor cells13–15. We confirmed key 
findings in immunophenotypically-defined skeletal stem cells isolated 
from total long bones of newborn mice16, which are homogeneous but 
limited in number.
Combined nutrient deprivation (CND; reduced levels of serum, 
oxygen, glucose and glutamine) increased SOX9 protein and mRNA 
levels in C3H10T1/2 or periosteal cells, without changes in expression 
of osteogenic, adipogenic or myogenic transcription factors (Fig. 2a, 
Extended Data Fig. 4a–c). Depriving C3H10T1/2 cells of individual nutri-
ents revealed that low oxygen levels increased SOX9, as reported17,18, 
whereas lowering glucose or glutamine levels had little effect 
(Fig. 2b). Unexpectedly, serum deprivation led to massive and rapid 
accumulation of SOX9 mRNA and protein, resulting from increased 
transcription and translation (Fig. 2b, Extended Data Fig. 4d–g). 
Expression of osteogenic, adipogenic and myogenic transcription 
factors did not change (Extended Data Fig. 4h). Serum deprivation 
also increased SOX9 in periosteal cells (Extended Data Fig. 4i) and 
enhanced their chondrogenic differentiation in micromass cultures 
(Fig. 2c), but prevented osteogenic differentiation (Extended Data 
Fig. 4j). A possible explanation for this chondrogenic switch is avoiding 
cell death. Indeed, knockdown of SOX9 in C3H10T1/2 cells, periosteal 
cells and growth plate-derived chondrocytes reduced cell viability in 
CND, and to a minor extent also in serum deprivation (Extended Data 
Fig. 4k, l). Thus, skeletal progenitor cells rapidly adapt to specific 
nutritional stress by increasing SOX9 levels and undergoing chon-
drogenic commitment.
Serum represents the main source of lipids, and we questioned 
whether serum deprivation-induced chondrogenic commitment of 
skeletal progenitors could be attributed to lipid deprivation. Resup-
plying C3H10T1/2 cells with oleate (Fig. 2d), palmitate, very low density 
lipoproteins or polyunsaturated fatty acids (PUFA) (Extended Data 
Fig. 5a–c) prevented the increase in SOX9 during serum deprivation. 
In addition, lipid-reduced serum (LRS) mimicked the effects of serum 
deprivation. LRS increased SOX9 levels in C3H10T1/2 cells (Fig. 2e), 
promoted chondrogenic differentiation of periosteal cells in micromass 
or pellet cultures, an effect partially reversed by exogenous fatty acids 
(Fig. 2f, Extended Data Fig. 5d), and inhibited their osteogenic differ-
entiation (Extended Data Fig. 5e). Importantly, serum deprivation or 
LRS also increased SOX9 levels in skeletal stem cells (Extended Data 
Fig. 5f). In all studied cell types, lipid deprivation increased the number 
of SOX9high cells, and cell cycle and apoptosis analysis showed this was 
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Fig. 1 | Preventing vascular ingrowth during bone healing induces 
chondrogenesis. a, Immunofluorescence analysis of bone-graft periosteal cell 
tracing showing contribution to cartilage and bone (arrows, GFP+ osteoblasts; 
arrowheads, GFP+ osteocytes) in the graft callus at PFD14, while CD31+ blood 
vessels (red) are mainly host-derived (representative images of 4 mice). Scale 
bars, 50 μm. b, Immunofluorescence analysis of a bone-autograft section 
revealing the interconnected periosteal callus and skeletal muscle vasculature 
at PFD7 (representative image of 3 mice). Scale bar, 200 μm. c, Schematic 
representation of the autograft model with filter. d, Immunohistochemical 
analysis and quantification of callus vascularization at PFD7 when a filter with 
30 μm (filter 30; arrows indicate blood vessels passing through filter pores) or 
0.2 μm (filter 0.2) pore size was placed in between muscle and graft (n = 4 mice 
for control and filter 30, n = 5 mice for filter 0.2). Scale bars, 50 μm in detail 
images, otherwise 200 μm. e, Visualization and quantification of early 
chondrogenic cells in the callus of grafts with or without a filter (0.2 μm) at 
PFD7 by immunofluorescence for SOX9 (n = 7 mice). Scale bars, 50μm.  
f, Visualization and quantification of cartilage in the callus of autografts with 
and without filter (0.2 μm) at PFD14 by immunofluorescence for collagen type 2 
(COL2) (n = 4 mice for control, n = 6 mice for filter 0.2). Scale bars, 500 μm.  
b, bone; c, cartilage; f, filter; g, graft; h, host; m, muscle; pc, periosteal callus. 
Data are mean ± s.e.m.; one-way ANOVA with Bonferroni post hoc test (d), two-
tailed Student’s t-test (e, f).
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not due to selection of a pre-existing SOX9high population (Extended 
Data Fig. 5f–h).
We next tested whether lipid availability also controls skeletal pro-
genitor differentiation in more physiologically relevant settings. Since 
it is not feasible to locally deprive cells specifically of exogenous lipids 
in vivo, we first used embryonic metatarsal cultures, an organ-like 
ex vivo model of bone development. Serum deprivation increased 
the number of SOX9+ chondrocytes and prevented osteogenesis, 
evidenced by absence of Col1a1-expressing cells and mineralization, 
which was reversed by fatty acid supplementation (Extended Data 
Fig. 5i, j). Second, local injection of fatty acids during fracture repair 
reduced the amount of cartilage in the callus, with no change in newly 
formed bone (Extended Data Fig. 5k). Third, GW9508, an agonist of 
free fatty acid receptor 1 (FFAR1) and FFAR4, prevented the increase 
in SOX9 induced by serum deprivation or LRS in the three cell models 
(Fig. 2g; Extended Data Fig. 5l). Accordingly, locally injecting GW9508 
during fracture repair decreased cartilage in the callus without affect-
ing woven bone areas (Fig. 2h). Together, low local lipid levels promote 
chondrogenesis of skeletal progenitor cells in vivo.
Our findings suggest that the chondrogenic switch during bone-
graft healing in the presence of a filter (Fig. 1) is primarily due to the 
absence of exogenous lipids, which is linked to poor vascularization. 
We found that diffusion of lipids in a collagen gel containing periosteal 
cells is much lower than that of glucose (Extended Data Fig. 5m), indi-
cating that lipids are a limiting nutrient when vascularization is inad-
equate. Furthermore, we showed that the absence of specific cell types, 
potentially blocked by the filter, does not impact chondrogenesis. 
Indeed, serum deprivation-supported chondrogenic differentiation 
of periosteal cells in micromass cultures was not prevented by mus-
cle-derived endothelial cells, macrophages or pericytes, in contrast 
to fatty acid supplementation. (Extended Data Fig. 5n, o). Together 
with our in vivo (Fig. 1) and in silico (Extended Data Fig. 3) results, 
this shows that lipid deprivation caused by reduced vascularization 
is probably an important determinant of periosteal chondrogenesis 
during bone healing.
Chondrocytes have low fatty acid oxidation
Why would chondrogenic commitment be beneficial when lipids are 
scarce? We hypothesized that chondrocyte metabolism does not rely 
on exogenous lipids. To test this, we compared the metabolic profile 
of chondrocytes to that of skeletal progenitors and mature osteoblasts 
(Fig. 3a, Extended Data Fig. 6a). Chondrocytes were highly glycolytic, 
as reported19,20. Osteoblasts showed the highest oxygen consumption 
rate (OCR), which was not owing to high glucose oxidation, but to a 
higher rate of fatty acid oxidation (FAO). Chondrocytes exhibited low 
FAO and skeletal progenitors had an intermediate profile. To confirm 
these findings in vivo, we examined metabolic-gene signatures in a 
mouse long-bone single-cell RNA-sequencing (RNA-seq) dataset that 
we generated recently21. This atlas encompasses 17 non-haematopoietic 
cell types including skeletal progenitors, chondrocytes and osteoblasts 
(Extended Data Fig. 6b). The different chondrocyte populations (clus-
ters 2, 10, 13, 17; Sox9+Acan+) showed low expression of FAO genes and 
high expression of glycolytic genes compared with osteoblasts (clus-
ters 7 and 8; Col1a1+Ocn+; Ocn is also known as Bglap) and, to a minor 
extent, skeletal progenitors (clusters 1 and 4; Grem1+) (Extended Data 
Fig. 6b, c). Gene expression analysis confirmed higher expression of 
the glycolytic genes Slc2a1 (encoding GLUT1), Pfkfb3 and Ldha, but 
lower expression of the FAO-related genes Cpt1a, Acadm and Acadl in 
growth plate cartilage versus cortical bone samples (Extended Data 
Fig. 6d). Immunohistochemistry showed low CPT1a levels and high 
GLUT1 levels in chondrocytes of the growth plate and fracture callus, 
whereas trabecular bone osteoblasts displayed high levels of both 
CPT1a and GLUT1 (Fig. 3b). Intravenous injection of fluorescent fatty 
acid and glucose analogues revealed labelled fatty acids in osteoblasts 
but not in chondrocytes in the growth plate or fracture callus, whereas 
labelled glucose was taken up by both cell types (Extended Data Fig. 6e, 
f), confirming that low FAO in chondrocytes correlates with lipid scar-
city. Transplantation experiments showed that loss of CPT1a abrogates 
osteogenic differentiation of skeletal stem cells during fracture healing 
but preserves their ability to become chondrocytes (Fig. 3c, Extended 
Data Fig. 6g). In addition, etomoxir, a CPT1 inhibitor, decreased viability 
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Fig. 2 | Lipid scarcity induces SOX9 in skeletal progenitors. a, b, Immunoblot 
detection of total SOX9 in C3H10T1/2 cells exposed for 24 h to control (C) or 
CND medium (a) or to different nutritional stresses (FBS, fetal bovine serum; 
Glc, glucose; Gln, glutamine) (b), with β-actin as loading control (n = 2 
independent experiments). c, Chondrogenic differentiation of periosteal cells 
in control or serum deprivation (SD) medium, assessed by visualization of 
chondrogenic matrix deposition (alcian blue staining) and quantification of 
Sox9, Col2a1 and Acan mRNA levels (relative to Actb, n = 6 biologically 
independent samples). d, e, Immunoblot detection of total SOX9 in C3H10T1/2 
cells exposed for 6 h to control medium, SD medium, SD medium 
supplemented with increasing concentrations of oleate (d) or LRS medium (e), 
with β-actin as loading control (n = 2 independent experiments).  
f, Chondrogenic differentiation of periosteal cells in control medium, LRS 
medium, SD medium or SD medium supplemented with 60 μM oleate (OL), 
assessed by alcian blue staining and quantification of Col2a1 and Acan mRNA 
levels (relative to Actb, n = 6 biologically independent samples). Veh, vehicle.  
g, Flow cytometric quantification of total SOX9 levels in periosteal cells 
exposed for 24 h to control medium, SD medium or LRS medium supplemented 
with 100 μM GW9508 (FFAR1/4 agonist) or vehicle (DMSO) (n = 3 biologically 
independent samples). h, Histological visualization (safranin O staining) and 
quantification of cartilage and woven bone in the callus at PFD7 of mice treated 
daily with GW9508 (10 nmol) or vehicle (0.2% DMSO in saline) at the fracture 
site (n = 5 mice). Scale bars, 500 μm. Data are mean ± s.e.m.; two-tailed 
Student’s t-test (c, h), one-way ANOVA (f) or two-way ANOVA (g) with 
Bonferroni post hoc test. For gel source data, see Supplementary Fig. 1.
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and numbers of cultured calvarial osteoblasts but not growth plate-
derived chondrocytes (Extended Data Fig. 6h). Thus, chondrocytes 
exhibit a low rate of FAO consistent with local lipid scarcity, and do not 
depend on this pathway to fulfil their metabolic demands.
SOX9 suppresses FAO
We next determined how lipid deprivation affects the rate of FAO in 
skeletal progenitor cells. As expected, oxidation of extracellular pal-
mitate immediately dropped after exposing periosteal cells to serum 
deprivation or LRS (Fig. 3d, Extended Data Fig. 7a). Surprisingly, cells 
temporarily maintained total FAO, which was quantified indirectly 
by measuring etomoxir-sensitive OCR22, for 6 h after serum depri-
vation (Fig. 3e, Extended Data Fig. 7b), suggesting that they initially 
compensate for the scarcity of exogenous lipids, possibly through 
mobilization of intracellular lipid stores. Indeed, fluorescent fatty 
acids translocated from lipid droplets into mitochondria, where FAO 
takes place, when periosteal cells were exposed to serum deprivation 
(Extended Data Fig. 7c). Starvation-induced lipid-droplet generation 
and breakdown are both linked to autophagy23,24, and we confirmed 
that C3H10T1/2 cells and periosteal cells activate autophagy early 
after serum deprivation (Extended Data Fig. 7d–f). Accordingly, 
lipid-droplet number initially increased during serum deprivation 
in C3H10T1/2 cells before decreasing at 6 h, and knockdown of the 
essential autophagosome protein ATG525 prevented both the initial 
increase and the late breakdown of lipid droplets after serum depriva-
tion (Extended Data Fig. 7g). Furthermore, the lysosomotropic drug 
chloroquine immediately reduced the FAO-linked OCR upon exposure 
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Fig. 3 | SOX9 suppresses FAO in chondrocytes. a, Quantification of glucose 
consumption and lactate secretion (PC, COB: n = 6; GCH: n = 5 biologically 
independent samples), glycolytic rate (n = 3 biologically independent samples), 
oxygen consumption (PC, COB: n = 7; GCH: n = 5 biologically independent 
samples), glucose oxidation (n = 3 biologically independent samples) and 
palmitate oxidation (n = 3 biologically independent samples) in periosteal  
cells (PC), growth plate-derived chondrocytes (GCH) and calvarial osteoblasts 
(COB). b, Analysis of adjacent histological sections of a growth plate  
and fracture callus (PFD7) by safranin O staining (cartilage) or 
immunofluorescence for CPT1a or GLUT1 (representative images of 3 mice). 
Scale bars, 100 μm. Dotted white lines delineate cartilage areas. c, Histological 
visualization and quantification of early chondrogenic (SOX9+) and osteogenic 
(COL1+) cells in the callus of fractures (PFD7) transplanted with CAG-DsRed+ 
skeletal stem cells (SSC) transduced with shRNA against Cpt1a (shCpt1a) or 
scrambled shRNA control (shScr) (n = 3 mice). Scale bars, 50 μm.  
d, Measurement of oxidation of extracellularly added palmitate by periosteal 
cells in control medium or at different times in SD medium (n = 3 biologically 
independent samples). e, Quantification of FAO-linked OCR in periosteal cells 
in control medium or at different times in SD medium (3h: n = 2, other time 
points: n = 3 biologically independent samples). f, Quantification of FAO-linked 
OCR in periosteal cells transduced with shSox9 or shScr in control medium or 
at different times in SD medium (shScr 12 h, shSox9 control, shSox9 3 h: n = 5; all 
others: n = 6 biologically independent samples). g, Quantification of FAO-
linked OCR in GCH transduced with shSox9 or shScr (n = 5 biologically 
independent samples). h, Quantification of palmitate oxidation in GCH 
transduced with shSox9 or shScr, and in COB transduced with a lentiviral vector 
encoding SOX9 (SOX9OE, SOX9 overexpression) or an empty vector (EV) (n = 4 
biologically independent samples). Data are mean ± s.e.m.; one-way ANOVA  
(a, d, e) or two-way ANOVA (f) with Bonferroni post hoc test, two-tailed 
Student’s t-test (c, g, h).
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of periosteal cells to serum deprivation (Extended Data Fig. 7h) and 
decreased survival of C3H10T1/2 cells and periosteal cells during serum 
deprivation (Extended Data Fig. 7i). Together, these data show that 
skeletal progenitors depend on lysosome-mediated mobilization of 
intracellular lipid stores to temporarily support FAO and secure survival 
when extracellular lipids become limited.
The increase in SOX9 levels (Extended Data Fig. 4d, e) and the 
decrease in total FAO (Fig. 3e) occur concomitantly after lipid dep-
rivation, suggesting that they are connected. Deletion of SOX9 in 
periosteal cells prevented the suppression of FAO by serum depriva-
tion (Fig. 3f), whereas inhibition of FAO with etomoxir did not alter 
SOX9 levels (Extended Data Fig. 7j). Moreover, knockdown of SOX9 in 
growth plate-derived chondrocytes induced not only loss of typical 
chondrocyte characteristics such as cobblestone-like morphology 
and expression of Col2a1 and Acan (Extended Data Fig. 7k, l), but also 
increased expression of Cpt1a and Acadl (Extended Data Fig. 7l) and the 
rate of FAO in chondrocytes (Fig. 3g, h). By contrast, overexpression of 
SOX9 in calvarial osteoblasts decreased FAO (Fig. 3h). SOX9 thus acts 
as a metabolic regulator in chondrogenic cells by suppressing FAO.
FOXOs induce SOX9 upon lipid starvation
We next examined how lipids regulate SOX9 levels. Transcriptomics 
showed robust upregulation of Sox9 expression in C3H10T1/2 cells 
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FAO. These adaptations promote cell survival and secure bone healing even in 
nutrient-poor environments. Data are mean ± s.e.m.; two-way ANOVA with 
Bonferroni post hoc test (e–g), two-tailed Student’s t-test (h, i). For gel source 
data, see Supplementary Fig. 1.
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starting 1 h after serum deprivation and increased expression of several 
other, but not all, chondrogenic markers from 3 h onwards (Extended 
Data Fig. 8a). Differential expression analysis showed that 678 (1 h), 
4,022 (3 h) and 3,811 (6 h) genes were significantly upregulated by serum 
deprivation, including Sox9 as one of the top hits at all time points 
(Fig. 4a, Extended Data Fig. 8b). A total of 757 (1 h), 2,167 (3 h) and 3,872 
(6 h) genes were significantly downregulated, including genes associ-
ated with proliferation (Egr3, Dusp5 and Errfi1), skeletal stem cells (Nes 
and Itga5) and osteogenesis (Spp1 and Adam19) (Fig. 4a; Extended Data 
Fig. 8b). Transcription factor-binding-motif analysis26 of the top-100 
overexpressed genes at each time point showed strong enrichment 
of the FOXO/forkhead motif (Fig. 4b, Extended Data Fig. 8c). We con-
firmed that serum deprivation increases nuclear FOXO1 and FOXO3a 
in C3H10T1/2 cells (Fig. 4c, d) and active FOXO levels in C3H10T1/2 
and skeletal stem cells, an effect prevented by exogenous fatty acids 
(Fig. 4e, Extended Data Fig. 8d–f), indicating that extracellular lipids 
control FOXO activity. More specifically, FOXO1 and FOXO3a showed 
increased binding to the Sox9 promoter during serum deprivation 
(Fig. 4f, Extended Data Fig. 8g), and the FOXO inhibitor AS1842856 
prevented induction of SOX9 during lipid deprivation in all cell types 
(Fig. 4g, Extended Data Fig. 8h). Similar results were obtained using 
a CRISPR–Cas9 approach to conditionally delete Foxo1 and Foxo3a 
(also known as Foxo3) in C3H10T1/2 cells, or using short hairpin RNAs 
(shRNAs) in skeletal stem cells (Extended Data Fig. 8i, j). These data 
demonstrate that FOXOs directly control Sox9 transcription during 
lipid deprivation.
We next confirmed the relation between lipid deprivation, FOXOs 
and SOX9 during bone healing. First, the presence of the filter 
(0.2 μm) during bone-graft healing increased the number of cells 
positive for nuclear FOXO3a in the central periosteal region (Fig. 4h), 
similar to the increase in SOX9+ cells (Fig. 1e). Second, stimulation 
of fatty acid signalling using the FFAR1/4 agonist GW9508 during 
fracture healing strongly reduced the number of FOXO3a+ nuclei 
in the periosteal callus (Extended Data Fig. 8k), correlating with 
reduced amounts of cartilage (Fig. 2h). Third, skeletal stem cells 
with FOXO1 and FOXO3 inactivation failed to engraft into tibial frac-
tures (Extended Data Fig. 8l), which may be owing to their inability 
to increase SOX9 levels upon lipid deprivation, or a general failure to 
survive transplantation-associated stress. Finally, local daily injection 
of the FOXO inhibitor AS1842856 during fracture healing reduced the 
amount of cartilage while not affecting new bone formation (Fig. 4i). 
Thus, FOXO signalling in vivo is negatively regulated by lipid avail-
ability and is required for skeletal progenitor cell chondrogenesis 
and survival during bone healing.
Discussion
On the basis of our findings, we propose a model in which the local 
vasculature, through supply of lipids, influences skeletal progenitor 
differentiation during fracture healing (Fig. 4j). Cells close to blood 
vessels become osteoblasts, which depend on FAO to support their 
metabolic demands. Skeletal progenitors in poorly vascularized regions 
sustain FAO for a short time by mobilizing intracellular lipid stores and 
then activate FOXO signalling as a result of exogenous lipid starvation. 
Nuclear localization of FOXOs promotes expression of SOX9, which 
induces chondrogenic commitment and suppresses FAO to allow long-
term cell survival.
Low lipid levels are thus the main nutritional determinant for chon-
drogenic commitment of skeletal progenitor cells, rather than lack of 
oxygen or glucose19,20,27, although growth factors are indispensable to 
activate the full chondrogenic-differentiation program1,2,9. In contrast 
to osteoblasts28,29, we find that chondrocytes are largely independ-
ent of FAO, consistent with poor diffusion of fatty acids in cartilage 
tissue. This metabolic independence from extracellular lipids would 
therefore be beneficial in the avascular cartilage environment. FAO in 
chondrocytes is suppressed by SOX9, attributing a novel metabolic 
regulatory role to this transcription factor. Mechanistically, reduced 
lipid availability is translated into SOX9 production through FOXOs, 
well-known regulators of the cellular response to metabolic stress30. 
We propose lipid starvation as an additional trigger for FOXO activa-
tion, although the full signalling cascade and exact lipid sensor remain 
unknown. Of interest, osteoarthritis is associated with increased angio-
genesis and FAO31,32 but reduced SOX9 levels and FOXO activity33,34. 
Our results show that all these phenomena may be connected to local 
lipid availability, suggesting that manipulation of lipid metabolism 
could be of therapeutic interest. More generally, our findings show 
that local nutrient levels can decide stem-cell lineage choice through 
direct transcriptional changes. As a consequence, the metabolic profile 
of a mature cell may reflect microenvironmental constraints as much 
as particular cellular needs.
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Methods
No statistical methods were used to predetermine sample size. The 
experiments were not randomized, unless otherwise mentioned. The 
investigators were not blinded to allocation during experiments and 
outcome assessment.
Mice
C57BL/6J mice, 129/Sv mice ( Janvier Labs), B6.Cg-Tg(CAG-eGFP) 
mice35, B6.Cg-Tg(Col1a1-cre/ERT2,-DsRed)1Smkm/J mice36, B6;129S4-
Sox9tm1.1Tlu/J mice and B6.Cg-Tg(CAG-DsRed*MST)1Nagy/J mice 
(The Jackson Laboratory) were used in this study. Unless otherwise 
specified, both male and female mice were used for all experiments. 
All animal experiments were conducted according to the regulations 
and with approval of the Animal Ethics Committee of the KU Leuven.
Mouse bone-healing models
The femoral segmental bone-graft model was adapted from a previ-
ously described model8. Eight- to ten-week old male C57BL/6J mice 
were anaesthetized with a ketamine–xylazine mixture (100 mg per kg 
ketamine and 15 mg per kg xylazine) and the right femur was exposed. 
A mid-diaphyseal 4-mm bone segment was excised with a 6.5-mm dia-
mond saw disk (Codema), briefly washed in saline to remove the bone 
marrow (periosteum not removed) and the segment was subsequently 
reimplanted in the defect (autograft). To investigate the contribution 
of donor cells, grafts were isolated from CAG-eGFP mice (periosteum 
not removed) and transplanted in wild-type littermates. To obtain 
devitalized allografts, 4-mm bone segments were isolated from 129/Sv 
mice, washed in saline to remove the bone marrow, scraped to remove 
the periosteum, sterilized in 70% ethanol and frozen at −80 °C for at 
least 1 week. After graft implantation, the defect was stabilized with an 
intramedullary metal pin (22 gauge needle). To create a compromised 
host environment, a polycarbonate filter with a pore size of 30 μm or 
0.2 μm (Sterlitech) was inserted between the muscle and the graft at 
the time of surgery.
The tibial fracture healing model was performed as previously 
described5. For studies with the FFAR1/4 agonist GW9508 mice were 
treated daily by subcutaneously injecting 50 μl of a 200 μM GW9508 
(Cayman Chemical) solution or vehicle (0.2% DMSO in saline) at the 
fracture site. For fatty acid delivery, mice were treated daily by subcu-
taneously injecting 20 μl corn oil (Sigma) or control solution (saline) 
at the fracture site. For studies with the FOXO inhibitor AS1842856, 
mice were treated daily by subcutaneously injecting 50 μl of a 10 μM 
AS1842856 (Calbiochem) solution or vehicle (0.1% DMSO in saline) 
at the fracture site. For metabolite labelling experiments mice were 
injected intravenously with the fluorescent fatty acid analogue BODIPY 
558/568 C12 (Red-C12; Invitrogen) at 1 mg per kg body weight and the 
fluorescent glucose analogue 2-(N-(7-nitrobenz-2-oxa-1,3-diazol-4-yl)
amino)-2-deoxyglucose (2-NBDG; Invitrogen) at 12.5 mg per kg body 
weight, 15 min before euthanasia. For skeletal stem cell transplanta-
tions, 100,000 cells (shCpt1a experiments) or 20,000 cells (shFoxo1 
and shFoxo3a experiments) were resuspended in 5 μl of a 5 mg ml−1 
collagen gel (rat tail collagen type I, Corning) and transplanted at the 
fracture site at the time of surgery.
Micro-computed tomography analysis
Mice were euthanised at 2 or 4 weeks after surgery and grafted bones 
were isolated. For bone analysis, samples were scanned using the high 
resolution SkyScan 1172 micro-computed tomography (microCT) sys-
tem (Bruker-microCT) at a pixel size of 10 μm with 50 kV tube voltage 
and 0.5 mm aluminium filter. To reduce the metal artefacts induced by 
the presence of the intramedullary pin, microCT projection data was 
reconstructed using an iterative reconstruction technique and projec-
tion completion37. Custom software was made in MeVisLab (MeVis Medi-
cal Solutions) to visualize and analyse the obtained microCT images. 
The boundary between graft and callus was manually delineated and 
mineralized tissue was segmented using hysteresis thresholding. For 
visual representation grafts are represented in a different colour to cal-
lus and host bone. The coverage ratio was calculated as the percentage 
of the graft surface that is covered with callus by determining whether 
the normal line to the graft surface encounters mineralized callus, for 
each point of the graft surface.
For visualization and quantification of the vasculature, mice were 
anaesthetized with a ketamine-xylazine-heparin mixture (100 mg per kg 
ketamine, 15 mg per kg xylazine and 1,000 U per kg heparin) and suc-
cessively perfused with 10 ml of heparinized saline (100 U ml−1), 10 ml 
of a 10% neutral-buffered formalin solution, 10 ml of saline and 5 ml 
of a preheated 30% barium sulfate solution (Micropaque, Guerbet) 
containing 2% gelatine. After perfusion, animals were placed on ice 
for at least 1 h and subsequently kept at 4 °C overnight to allow the 
gelatine to solidify, before removing the grafted hindlimbs for dual-
energy microCT analysis38,39. Two microCT scans of each sample were 
taken on the SkyScan 1172 microCT system with effective beam energy 
below (50 kV tube voltage with 0.5 mm aluminium filter) and above 
(100 kV tube voltage with 0.5 mm aluminium and 0.038 mm copper 
filter) the K-edge energy of barium sulfate, both with an image pixel size 
of 5 μm. By combining the low and high energy acquisitions, an image 
of the (barium sulfate-perfused) vasculature only was reconstructed 
as described38,39 and a segmentation of the vasculature was obtained 
by thresholding this image. A segmentation of the bone was obtained 
by thresholding the bone and vasculature out of the low energy recon-
struction and removing the calculated vasculature from it. After delin-
eating a 250-μm-wide region of interest around the graft surface using 
a custom made MeVisLab software package, calculation of the number 
of blood vessels and the average vessel thickness was performed using 
the CTAn software (Bruker-microCT).
Immunohistochemistry
To isolate bones for histological analysis, mice were anaesthetized 
with ketamine–xylazine–heparin and perfused with 10 ml of heparin-
ized saline followed by 10 ml of 2% paraformaldehyde in PBS. Isolated 
bones were further fixed in 2% paraformaldehyde overnight and 
decalcified in EDTA for 14 days at 4 °C. Samples were either embed-
ded in paraffin and sectioned at 4 μm, embedded in agarose for 
vibratome sections (100 μm thick) or embedded in NEG-50 frozen sec-
tion medium (Richard-Allen Scientific) and sectioned at 7 μm using 
the CryoJane Tape-Transfer System (Leica) for samples containing 
fluorescent protein-expressing cells. Staining with haematoxylin and 
eosin (H&E) and safranin O, terminal deoxynucleotidyl transferase 
dUTP nick end labelling (TUNEL) staining and immunohistochemical 
staining for BrdU, CD31 and COL2 are routinely used in our labora-
tory and have all been described previously5,13,40–43,. For SOX9, COL1, 
CPT1a, GLUT1 and FOXO3a immunohistochemical staining, sections 
were deparaffinised and blocked for 30 min in 0.1 M Tris-HCl, 0.15 M 
NaCl, pH 7.6 (TNT) with 0.5% Blocking Reagent (NEN, PerkinElmer) 
and 20% normal goat serum (DAKO). Subsequently, sections were 
incubated overnight with a rabbit anti-SOX9 primary antibody (Novus 
Biologicals; NBP1-85551; 1:100), rabbit anti-COL1 primary antibody 
(Novus Biologicals; NB600-408; 1:100), rabbit anti-CPT1a primary 
antibody (Cell Signaling Technology; no. 12252; 1:50), rabbit anti-
GLUT1 primary antibody (Cell Signaling Technology; no. 12939; 1:100) 
or rabbit anti-FOXO3a primary antibody (Cell Signaling Technol-
ogy, no. 2497, 1:100) diluted in TNT with 0.5% blocking reagent, fol-
lowed by three washes with TNT containing 0.05% Tween-20. Next, 
slides were incubated for 1 h with an Alexa Fluor 546- or Alexa Fluor 
488-conjugated goat anti-rabbit secondary antibody (Invitrogen; 
A-11010 and A-11034) diluted 1:200 in TNT/0.5% blocking reagent, 
washed and counterstained with Hoechst 33342 (20 μg ml−1 in PBS; 
Invitrogen). Stainings omitting the primary antibody were used as 
negative controls.
Images were taken on a Zeiss Axioplan 2 light microscope, Zeiss 
LSM510-META NLO multi-photon confocal microscope or Zeiss 
LSM880 confocal laser scanning microscope. Histomorphometry 
was performed using the Zeiss AxioVision software, ImageJ software 
(National Institutes of Health) and CellProfiler software44. Quantifica-
tion of blood vessels or proliferating cells was performed by respec-
tively counting CD31+ vessels or BrdU+ cells in a 250-μm-wide region 
of interest adjacent to the graft surface. Apoptotic or chondrogenic 
cells were quantified by respectively counting the number of TUNEL+ 
or SOX9+ cells and the total number of cells in a 0.015 mm2 region of 
interest near the graft surface at the centre of the graft. Quantification 
of cartilage was performed by outlining COL2+ or safranin O+ areas 
within the total callus area (for fractures and grafts) or the central graft 
callus area (half of total graft length). Quantification of woven bone was 
performed by outlining areas of macroscopically-defined immature 
bone within the total callus area. Quantification of FOXO3a+ nuclei 
was performed using the ‘cell/particle counting and scoring’ pipeline 
in CellProfiler, in a region of interest encompassing the total callus 
area (for fractures) or the central graft callus area (half of total graft 
length). For all quantifications, measurements were made on at least 
three different sections throughout the sample.
Computational model of bone-graft healing
We used a previously established multiscale computational frame-
work of bone regeneration that quantitatively describes the interplay 
between cells, growth factors, nutrient levels and blood vessels10,11. In 
short, this multiscale model combines ten partial differential equations 
of the taxis-reaction-diffusion type at the tissue level with a discrete 
agent-based approach at the vascular level, including eight intracel-
lular variables for the endothelial cells. At the tissue level, the model 
accounts for the various key processes of intramembranous and endo-
chondral ossification that occur during the soft and hard callus phase of 
bone healing. The partial differential equations describe the evolution 
in time and space of the skeletal progenitor cell density, fibroblast den-
sity, chondrocyte density, osteoblast density, fibrous matrix density, 
cartilaginous matrix density, bone matrix density, osteochondrogenic 
growth factor concentration, vascular growth factor concentration 
and nutrient concentration. For simplification purposes, only one 
generic osteochondrogenic growth factor and one nutrient parameter 
is included in the computational model, which respectively repre-
sent the effects of multiple growth factors (for example, transforming 
growth factors or bone morphogenetic proteins) and nutrients (such 
as oxygen, glucose, amino acids or lipids) present during bone heal-
ing. The assumption is made that the net result of all growth factors 
present will be to promote chondrogenesis and osteogenesis, and 
thus if local levels of the osteochondrogenic growth factor reach a 
certain threshold (modelled using a sixth-order Hill function) it will 
induce differentiation of skeletal progenitor cells. The decision on 
whether the end result of this differentiation event is chondrogenic 
or osteogenic is made by the nutrient parameter. The influence of the 
generic osteochondrogenic growth factor on skeletal progenitor cell 
differentiation is promoting chondrogenic differentiation when local 
nutrient levels are low, and promoting osteogenic differentiation when 
local nutrient levels are high. Cell types that are considered at the tissue 
scale (skeletal progenitor cells, chondrocytes, osteoblasts, fibroblasts) 
can migrate (only skeletal progenitor cells and fibroblasts), prolifer-
ate, differentiate and produce growth factors (generic osteochondro-
genic growth factor or angiogenic growth factor) and extracellular 
matrix (cartilage, bone or fibrous tissue). Blood vessels are modelled 
at both a cellular level (representing the developing vasculature with 
discrete endothelial cells) and an intracellular level (that defines the 
internal dynamics of every endothelial cell), and serve as the nutrient 
source. At the cellular level, the development of the discrete vascular 
tree (composed of endothelial cells) is determined by three different 
processes, that is, sprouting (the formation of a new branch, headed 
by a tip endothelial cell), vascular growth (the extension of the branch 
due to tip cell migration) and anastomosis (the fusion of two branches). 
An anastomosis between blood vessels allows for blood flow and the 
delivery of nutrients. The intracellular level considers a number of 
molecular players that govern endothelial cell movement (VEGFR2, 
DLL4, Notch and actin).
While the blood vessels are modelled discretely, continuous vari-
ables are used for nutrient density, bone density, cartilage density and 
fibrous tissue density (included in the model but not relevant for the 
current setup and therefore not shown). The colour scale for nutrients, 
bone and cartilage thus indicates a continuous gradient going from 
complete absence of a parameter (‘0’ value; nutrients, bone or cartilage 
are not present at that location) to complete saturation of a parameter 
(‘1’ value; a location is completely filled with nutrients, bone or carti-
lage). All values in between 0 and 1 represent partial filling of a location 
with a parameter. For the ‘tissue’ continuous variables (bone, cartilage, 
fibrous tissue), the sum of all tissues is 1, meaning that if a location 
is completely filled with bone (value ‘1’), no cartilage can exist at the 
same location (value ‘0’). However, since the variables are continuous, 
a specific location can contain both a fraction of bone and a fraction of 
cartilage. Tissues, nutrients and blood vessels are modelled in separate 
spaces and can thus ‘co-exist’ in the same location. Since the nutrient 
parameter is also continuous, it has an independent scale going from no 
nutrients (value ‘0’) to saturating levels of nutrients (value ‘1’, which we 
define as the level of nutrients found inside a modelled blood vessel).
By adapting the geometry and boundary conditions to the bone-graft 
setup, the influence of a filter placed in between graft and muscle on 
the healing process can be predicted in silico. Detailed information on 
the equations, parameter values and implementation can be found in 
ref. 11. Information on the boundary and initial conditions used in this 
study can be found in Extended Data Fig. 3.
Isolation of primary cells
Periosteal cells and trabecular osteoblasts were isolated from the long 
bones of 8–10-week-old mice as described13. For the isolation of peri-
osteal cells, femurs and tibias were dissected free of muscle and con-
nective tissue under sterile conditions. Subsequently, the epiphyses 
were protected from digestion by submerging them in 5% low melting 
point agarose (SeaPlaque, Lonza) and periosteal cells were isolated by 
enzymatic digestion using 3 mg ml−1 collagenase II (Gibco) and 4 mg ml−1 
dispase (Gibco) in α-minimal essential medium (α-MEM; Gibco) supple-
mented with 1% penicillin/streptomycin (100 units ml−1 and 100 μg ml−1 
respectively; Gibco). Cells from the first digest (10 min) were discarded 
as they contain cells from remaining muscle and connective tissue, and 
periosteal cells were obtained by a subsequent 1 h digest. The cells were 
passed through a 70-μm nylon mesh (BD Falcon), washed twice and cul-
tured in α-MEM with 1% penicillin/streptomycin and 10% FBS (HyClone) 
in a humidified incubator at 37 °C with 5% CO2. For the isolation of 
trabecular osteoblasts, femurs and tibias were cleaned thoroughly 
to remove muscle, connective tissue and periosteum. Subsequently, 
bones were incubated in collagenase–dispase (3 mg ml−1 collagenase 
II and 4 mg ml−1 dispase in α-MEM with 1% penicillin/streptomycin) for 
20 min to remove remaining periosteal cells. Next, epiphyses were cut 
away, bone marrow was flushed out and the bone was cut into small 
pieces. Trabecular osteoblasts were isolated by incubating the bone 
fragments with collagenase–dispase for 30 min. Cells were passed 
through a 70-μm nylon mesh, washed twice and cultured in α-MEM 
supplemented with 1% penicillin/streptomycin and 10% FBS at 37 °C 
with 5% CO2. Cells from passage 2–3 were used for all experiments.
Growth plate-derived chondrocytes and calvarial osteoblasts were 
isolated from 3–5-day-old mice as described13,20. For murine growth 
plate-derived chondrocytes the resting zones of the growth plates 
from the distal femora and proximal tibiae were dissected free from 
surrounding tissue and pre-digested for 30 min with 1 mg ml−1 col-
lagenase II in α-MEM with 1% penicillin/streptomycin on a shaker at 
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room temperature. Cartilage fragments were then washed twice and 
subsequently digested for 3 h in a 2 mg ml−1 collagenase II solution in 
α-MEM with 1% penicillin/streptomycin on a shaker at 37 °C. The cell 
suspension was then filtered through a 40-μm nylon mesh, washed and 
cultured in α-MEM supplemented with 1% penicillin/streptomycin and 
10% FBS at 37 °C with 5% CO2. Calvarial osteoblasts were prepared by 6 
sequential 15-min digestions of calvaria from 3–5-day-old mice in PBS 
containing 1 mg ml−1 collagenase II and 2 mg ml−1 dispase. Cells isolated 
in fractions 2–6 were pooled and cultured in α-MEM supplemented 
with 1% penicillin/streptomycin and 10% FBS at 37 °C with 5% CO2. Cells 
from passage 2–3 were used for all experiments.
For isolation of rib chondrocytes, anterior rib cages were dissected 
from 5-day-old mice. Isolated rib cages were pre-digested on a shaker 
for 30 min at room temperature with 1 mg ml−1 collagenase II (Gibco) 
dissolved in α-MEM supplemented with 1% penicillin/streptomycin. 
Rib fragments were subsequently digested for 3 h in a 2 mg ml−1 col-
lagenase II solution in α-MEM with 1% penicillin/streptomycin on a 
shaker at 37 °C. The obtained cell suspension of the second digest 
was filtered through a 40-μm nylon mesh and single cells were recov-
ered by centrifugation. Cells were cultured in a humidified incuba-
tor at 37 °C with 5% CO2 in α-MEM supplemented with 1% penicillin/
streptomycin and 10% FBS. Cells from passage 2–3 were used for all 
experiments.
Isolation of mouse skeletal stem cells was adapted from a previ-
ously described protocol16. Long bones of 3–5-day-old mice were 
dissected, muscle was cleared away carefully to preserve the perios-
teum and bones were minced using a scalpel. Bone fragments were 
then digested in α-MEM supplemented with 3 mg ml−1 collagenase II, 
4 mg ml−1 dispase (both from Gibco) and 100 U ml−1 DNase I (Sigma) 
at 37 °C for 3 sequential 15-min digests. Cell fractions were pooled 
and passed through a 70-μm nylon mesh, washed with PBS contain-
ing 2% FBS and stained with antibodies against CD45, TER119, TIE2, 
CD105, CD90.2, CD249 (also known as 6C3) (BioLegend), CD51 (BD 
Pharmingen) and CD200 (eBioscience), and with the viability dye 
7-aminoactinomycin D (7AAD; BD Pharmingen). Immunophenotyp-
ically-defined skeletal stem cells16 (7AAD−CD45−TER119−TIE2−CD51+
CD105−CD90.2−CD249−CD200+; Extended Data Fig. 9a) were sorted 
on a BD FACSAria II (BD Biosciences). Single colour controls were 
used to set compensations and fluorescence minus one controls 
were used to set gates. Sorted cells were cultured in a humidified 
incubator at 37 °C with 2% O2 and 7.5% CO2 in α-MEM supplemented 
with 1% penicillin/streptomycin and 10% FBS. For metabolic analyses, 
skeletal stem cells were grown in atmospheric O2 levels with 5% CO2 
to enable direct comparison with other cell types. Cells from passage 
2–3 were used for all experiments. For flow cytometric analysis of 
culture-expanded skeletal stem cells, cells were gated again for the 
CD51+CD105−CD90.2−CD249−CD200+ population to limit analysis to 
the stem cell fraction.
For the isolation of skeletal muscle-derived cell populations, 
hindlimb skeletal muscles, including quadriceps, soleus, gastrocne-
mius and tibialis anterior, were dissected from 8-week-old CAG-DsRed 
mice, minced using a scalpel and digested in α-MEM medium supple-
mented with 3 mg ml−1 collagenase II, 4 mg ml−1 dispase and 100 U ml−1 
DNase I at 37 °C for 60 min. Every 15 min, samples were pipetted up 
and down vigorously using a 10-ml serological pipette to break up tis-
sue fragments. Cell suspensions were passed through a 70-μm nylon 
mesh, washed with PBS containing 2% FBS and stained with antibodies 
against CD45, TER119, CD31, F4/80 and CD146 (BioLegend), and with 
7AAD (BD Pharmingen). Immunophenotypically-defined macrophages 
(7AAD−CD45+F4/80+), endothelial cells (7AAD−CD45−TER119−F4/80−C
D31+CD146+) and pericytes (7AAD−CD45−TER119−F4/80−CD31−CD146+) 
(Extended Data Fig. 9b) were sorted on a BD FACSAria II. Single colour 
controls were used to set compensations and fluorescence minus one 
controls were used to set gates. Sorted cells were used for co-cultures 
with periosteal cells in micromasses.
Cell lines
The C3H10T1/2 cell line, used as a skeletal progenitor cell model12, was 
obtained from the RIKEN Cell Bank and cultured in a humidified incuba-
tor at 37 °C with 5% CO2 in α-MEM with 1% penicillin/streptomycin and 
10% FBS. Cells were routinely tested and found negative for mycoplasma 
contamination.
Nutrient-deprivation assays
Cells were seeded at 3,000 cells per cm2 in basal DMEM (glucose- and 
glutamine-free; Gibco) supplemented with 1% penicillin/streptomycin, 
5 mM d-(+)-glucose (Sigma-Aldrich), 2 mM l-glutamine (Gibco), 1 mM 
sodium pyruvate (Gibco) and 10% dialysed FBS (HyClone). After 24 h, 
cells were washed with PBS and switched to control medium (basal 
DMEM with 1% penicillin/streptomycin, 5 mM glucose, 2 mM l-glu-
tamine, 1 mM sodium pyruvate and 10% dialysed FBS), SD medium 
(basal DMEM with 1% penicillin/streptomycin, 5 mM glucose, 2 mM 
l-glutamine, 1 mM sodium pyruvate and 1% dialysed FBS), glucose-
deprivation medium (basal DMEM with 1% penicillin/streptomycin, 
0.5 mM glucose, 2 mM l-glutamine, 1 mM sodium pyruvate and 10% 
dialysed FBS), glutamine-deprivation medium (basal DMEM with 1% 
penicillin/streptomycin, 5 mM glucose, 0.2 mM l-glutamine, 1 mM 
sodium pyruvate and 10% dialysed FBS), CND medium (basal DMEM 
with 1% penicillin/streptomycin, 0.5 mM glucose, 0.2 mM l-glutamine, 
1 mM sodium pyruvate and 1% dialysed FBS) or LRS medium (basal 
DMEM with 1% penicillin/streptomycin, 5 mM glucose, 2 mM l-glu-
tamine, 1 mM sodium pyruvate and 10% lipid-reduced FBS). LRS was 
made by mixing FBS with fumed silica (Sigma) at 20 mg ml−1 for 3 h at 
room temperature, followed by centrifugation at 2,000g for 15 min 
and filtration of the supernatant through a 0.45-μm-pore-size filter.
In certain experiments cultures were supplied with actinomycin 
D (transcription inhibitor; Sigma-Aldrich), cycloheximide (transla-
tion inhibitor; Sigma-Aldrich), chloroquine (lysosomal inhibitor; 
Sigma-Aldrich) or etomoxir (CPT1 inhibitor; Merck–Millipore) at the 
concentrations indicated in the text. For lipid rescue experiments, SD 
medium was supplemented with very low density lipoproteins (VLDL; 
Calbiochem) at a concentration of 607 μg triglycerides per ml FBS, 
palmitic or oleic acid (Sigma-Aldrich) at the indicated concentrations 
or a mixture of PUFAs (10 μM linoleic acid, 15 μM α-linolenic acid, 10 μM 
arachidonic acid and 15 μM docosahexaenoic acid; all from Sigma-
Aldrich). Triglycerides were incubated in FBS for 30 min at 37 °C and 
fatty acids (dissolved in ethanol) were complexed to fatty acid-free 
bovine serum albumin (BSA) (Sigma-Aldrich) for 1 h at 37 °C before 
adding to the culture medium, as described previously45. All supple-
ments were added at the start of the experiment and were present for 
the entire duration of the cultures.
Differentiation assays
To assess chondrogenic differentiation, 150,000 periosteal cells were 
resuspended in 10 μl of control medium and seeded as micromasses 
in the middle of a 24-well plate. Cells were allowed to attach for 1 h 
at 37 °C, after which 0.5 ml of control, SD or LRS medium containing 
10 ng ml−1 recombinant human TGFβ1 (Peprotech), 50 μM l-ascorbic 
acid 2-sulfate (Sigma-Aldrich) and 20 μM Y-27632 (Rho kinase inhibi-
tor; Axon Medchem)46 was added to the wells. Medium was refreshed 
every other day and after 9 days micromasses were either stained with 
alcian blue or used for RNA isolation. For chondrogenic differentia-
tion in the presence of muscle-derived cells micromasses were made 
using 100,000 periosteal cells derived from Sox9-GFP mice and 50,000 
skeletal muscle-derived macrophages, endothelial cells, pericytes or 
unsorted cells obtained from CAG-DsRed mice.
For chondrogenic differentiation in pellets 200,000 periosteal cells 
were placed in a 5-ml polystyrene tube in 1 ml of control, SD or LRS 
medium containing 10 ng ml−1 recombinant human TGFβ1 (Peprotech) 
and 50 μM l-ascorbic acid 2-sulfate (Sigma-Aldrich), supplemented with 
vehicle (1% ethanol in 4% fatty acid-free BSA in saline), 60 μM oleate or 
a mixture of PUFA (10 μM linoleic acid, 15 μM α-linolenic acid, 10 μM 
arachidonic acid and 15 μM docosahexaenoic acid) complexed to fatty 
acid-free BSA. Tubes were centrifuged for 5 min at 500g and placed in a 
humidified incubator at 37 °C. Medium was changed every 3 days and 
after 21 days pellets were fixed in 4% paraformaldehyde for 10 min and 
processed for paraffin histological sectioning.
For osteogenic differentiation, periosteal cells were seeded cells 
at 30,000 cells per cm2 in control medium and cultured for 3 days in 
order to reach full confluence. Cells were then switched to control, SD 
or LRS medium containing 50 μM l-ascorbic acid 2-sulfate and 10 mM 
β-glycerophosphate (Sigma-Aldrich). After 21 days, cells were either stained 
with alizarin red S to detect mineralization or used for RNA isolation.
Metatarsal cultures
Metatarsal rudiments were dissected from E16.5 Col1a1-cre/ERT2, 
-DsRed embryos and stripped of skin. The middle three metatarsals 
were kept together as triads and cultured for 7 days on a Falcon insert 
membrane (pore size 0.4 μm) in 12-well plates in 1 ml of BGJb culture 
medium (Gibco) supplemented with 25 μg ml−1 l-ascorbic acid 2-sulfate, 
10 mM β-glycerophosphate, and FBS (10% or 1%)40. When indicated a 
mixture of PUFAs (10 μM linoleic acid, 15 μM α-linolenic acid, 10 μM 
arachidonic acid and 15 μM docosahexaenoic acid) complexed to fatty 
acid-free BSA or vehicle (1% ethanol in 4% fatty acid-free BSA in saline) 
was added to the culture medium. At the end of the cultures the metatar-
sals were fixed overnight in 2% paraformaldehyde in PBS and processed 
for histochemistry or immunohistochemistry.
Flow cytometry
Cell death was detected using annexin V–FITC and propidium iodide 
(Dead Cell Apoptosis Kit; Invitrogen), or using active caspase 3–FITC 
(FITC Active Caspase-3 Apoptosis Kit; BD Pharmingen). Proliferation 
was assessed by staining with a PE-conjugated mouse anti-Ki-67 anti-
body (BD Pharmingen; #556027; 1:10) and Hoechst 33342 (40 μg ml−1; 
Invitrogen) after fixation and permeabilization of the cells (BD Cytofix/
Cytoperm Kit, BD Biosciences). Intracellular SOX9 levels were quanti-
fied by staining with an Alexa Fluor 647-conjugated rabbit anti-SOX9 
antibody (Cell Signaling Technology; no. 71273; 1:100) after fixation and 
permeabilization of the cells. Gating for SOX9high cells was set to have 
approximately 10% SOX9high cells in control conditions. Single colour 
controls were used to set compensations and fluorescence minus one 
controls were used to set gates.
Immunocytochemistry
For immunofluorescence microscopy, cells grown on coverslips were 
fixed with 4% paraformaldehyde, permeabilized with 0.5% Triton-X100 
in PBS and blocked with PBS containing 5% BSA, 5% normal goat serum 
and 0.5% Tween-20. Next, cells were incubated overnight at 4 °C with 
primary antibodies (rabbit anti-FOXO1, Cell Signaling Technology, 
no. 2880, 1:100; rabbit anti-FOXO3a, Cell Signaling Technology, no. 
2497, 1:100) in blocking buffer, followed by three washes with PBS/
Tween-20. Slides were subsequently incubated for 2 h with secondary 
antibodies (Alexa Fluor 488-conjugated goat anti-rabbit; 1:500) in PBS 
containing 5% BSA and 0.5% Tween-20, washed and counterstained 
with Hoechst 33342. Stainings omitting the primary antibody were 
used as negative controls.
For staining of lipid droplets with 1,6-diphenyl-1,3,5-hexatriene 
(DPH), cells grown on coverslips were washed with PBS and fixed with 
3.7% formaldehyde in PBS. DPH staining solution was prepared by 
diluting a 2 mM DPH (Sigma-Aldrich) stock (in DMSO) in PBS to a final 
concentration of 4 μM as previously described47. Cells were stained 
with DPH for 30 min, washed and nuclei were counterstained using 
TO-PRO-3 (Molecular Probes).
For tracking lipid movement between lipid droplets and mitochon-
dria, cells were incubated with the fluorescent fatty acid analogue 
BODIPY 558/568 C12 (Red-C12; Invitrogen) at 1 μM in culture medium for 
16 h (ref. 24). Cells were then washed three times with culture medium, 
incubated for 1 h in culture medium to allow the fluorescent lipids to 
incorporate into lipid droplets, and then chased for the time indicated 
in control or SD medium. Mitochondria were labelled with 100 nM 
MitoTracker Deep Red FM (Invitrogen) for 30 min before the end of 
the experiment. Cells were fixed and lipid droplets were stained with 
DPH as described above.
For measurement of autophagic flux, cells grown on coverslips were 
transfected with 1 μg of an RFP-GFP-LC3 tandem construct48 using the 
X-tremeGENE HP transfection reagent (Roche) according to the manu-
facturer’s instructions. After 24 h, cells were washed with PBS and used 
for subsequent experiments. Since the GFP–LC3 loses fluorescence 
owing to lysosomal acidic and degradative conditions but the RFP–LC3 
does not, autophagosomes in the cell are seen as green–yellow puncta, 
whereas autophagolysosomes are red.
Images were taken on a Zeiss LSM510-META NLO multi-photon confo-
cal microscope or Zeiss LSM880 confocal laser scanning microscope, 
and prepared using Adobe Photoshop CS5 (Adobe) and ImageJ. LC3 
puncta and DPH+ lipid droplets per cell were counted manually in 
ImageJ, while overlap between MitoTracker and Red-C12 in manually 
delineated cells was performed using the ‘co-localization’ plugin for 
ImageJ after thresholding of individual frames.
Western blot analysis
Total cell lysates were obtained by lysing cells in 25 mM Tris-HCl buffer 
(pH 7.6) containing 150 mM NaCl, 1% NP-40, 1% sodium deoxycholate, 
0.1% SDS, 1× cOmplete protease inhibitor cocktail (Roche) and 1× 
PhosSTOP phosphatase inhibitor cocktail (Roche). For cytoplasmic 
and nuclear extracts, cells were first lysed in 20 mM Hepes (pH 7.9) 
containing 10 mM KCl, 1.5 mM MgCl2, 1 mM EDTA, 0.5% NP40, 1 mM 
DTT, 1 mM Na3VO4, 20 mM NaF, 1 mM PMSF, 5 μg ml
−1 aprotinin, 5 μg ml−1 
leupeptin and 0.33 μg ml−1 antipain. Following 15 min incubation at 
4 °C, the cell lysates were passed 10 times through a 26 gauge needle. 
After centrifugation for 1 min at 18,000g, the supernatant (cytoplasmic 
proteins) was removed and the pellet containing the nuclear protein 
fraction was resuspended in 50 mM Hepes (pH 7.9) containing 500 mM 
NaCl, 1% NP40, 5 μg ml−1 aprotinin, 5 μg ml−1 leupeptin and 0.33 μg ml−1 
antipain, and sonicated. Proteins (10 μg, except for detection of LC3 for 
which 20 μg was used) were separated by SDS–PAGE and transferred to 
a nitrocellulose membrane (GE Healthcare). Membranes were blocked 
with 5% dry milk in Tris-buffered saline with 0.1% Tween-20 for 30 min 
at room temperature and incubated overnight at 4 °C with primary 
antibodies (rabbit anti-SOX9, Novus Biologicals, NBP1-85551, 1:2,000; 
rabbit anti-FOXO1, Cell Signaling Technology, no. 2880, 1:1,000; rab-
bit anti-FOXO3a, Cell Signaling Technology, no. 2497, 1:1,000; rabbit 
anti-LC3B, Cell Signaling Technology, no. 3868, 1:500; mouse anti-
β-actin, Sigma, A5441, 1:10,000; mouse anti-lamin A/C, Santa Cruz 
Biotechnology, sc-376248, 1:5,000) diluted in blocking buffer. Signals 
were detected by enhanced chemiluminescence (Perkin Elmer) after 
incubation with HRP-conjugated secondary antibodies (DAKO). For 
gel source data, see Supplementary Fig. 1.
Metabolic assays
Glucose and lactate levels in culture medium were measured on a 
AU640 Chemistry Analyzer (Beckman Coulter). Glucose consump-
tion was calculated by subtracting the remaining amount of glucose in 
the culture medium after 24 h of incubation with cells from the amount 
of glucose in unspent medium, and normalized for time and for cell 
number via DNA quantification. In a similar way, lactate secretion was 
calculated by subtracting lactate levels in unspent medium from the 
levels in medium incubated for 24 h with cells. Oxygen consumption 
was determined on a Seahorse XF24 Analyzer (Seahorse Bioscience) 
using 50,000 cells per well. The assay medium was unbuffered DMEM 
(Sigma) supplemented with 5 mM d-glucose and 2 mM l-glutamine, 
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pH 7.4. For quantification of FAO-linked oxygen consumption the dif-
ference in OCR before and after injection of etomoxir (100 μM final 
concentration) was calculated22.
For measurement of glycolysis, cells were incubated for 6 h in growth 
medium containing 0.3 μCi ml−1 [5-3H]d-glucose (PerkinElmer). The 
culture medium was then transferred into glass vials sealed with rub-
ber caps. 3H2O was captured in hanging wells containing a Whatman 
paper soaked with H2O over a period of 48 h at 37 °C to reach satura-
tion49. Radioactivity was determined in the paper by liquid scintillation 
counting and values were normalized to DNA content.
For glucose oxidation, cells were incubated for 6 h in growth medium 
containing 0.6 μCi ml−1 [6-14C]d-glucose (PerkinElmer). To stop cellular 
metabolism, 250 μl of a 2 M perchloric acid solution was added and wells 
were covered with a Whatman paper soaked with 1x hyamine hydroxide. 
14CO2 released during the oxidation of glucose was absorbed into the 
paper overnight at room temperature. Radioactivity in the paper was 
determined by liquid scintillation counting, and values were normal-
ized to DNA content49.
FAO was measured after incubation of the cells with 3 μCi ml−1  
[9,10-3H]palmitate (PerkinElmer), complexed to BSA, for 2 h. Then, 
the culture medium was transferred into glass vials sealed with rub-
ber caps. 3H2O was captured in hanging wells containing a Whatman 
paper soaked with H2O over a period of 48 h at 37 °C. Radioactivity in 
the paper was determined by liquid scintillation counting, and values 
were normalized to DNA content49.
Metabolite diffusion assay
Diffusion rates were measured in custom-designed diffusion chambers 
according to a previously established protocol50. Chambers were fab-
ricated in a polydimethylsiloxane (PDMS) device on a glass substrate 
with medium reservoirs that contained fluorescent tracer molecules. 
2-NBDG (342 Da) and BODIPY FL C16 (FL-C16; Invitrogen) complexed 
to fatty acid-free BSA (66.5 kDa) were used as fluorescent analogues to 
evaluate the diffusion rates of glucose and fatty acids, respectively, in 
separate runs. Tracer movement was assessed in square borosilicate 
glass capillaries with an inner width of 0.8 mm and wall thickness of 
0.16 mm (VitroCom). Collagen type I gels (5 mg ml−1) containing peri-
osteal cells (5 million per ml) were polymerized within the capillaries, 
after which the capillaries were connected to the PDMS reservoirs which 
initiated the diffusion process resulting from a concentration gradient 
between the tracer saturated medium reservoir (250 μM 2-NBDG or 
25 μM FL-C16 complexed to 25 μM BSA) and the tracer-free capillary. 
Tracer gradients within the capillaries were imaged on a confocal fluo-
rescence laser scanning microscope (FV1000, Olympus) equipped with 
a UPLSAPO 10× air objective (NA 0.40) focused on the middle plane 
of the collagen gel. Focus drift was compensated using an IX81-ZDC 
module that focuses a 785-nm laser on the glass capillary surface to 
stably reproduce the focus position for each capillary position and for 
every acquisition time point. Images were acquired as a time series with 
10-min intervals over a total period of 5 h, at 37 °C. Tracer-free collagen 
gels were visualized to correct the image sequences for any background 
fluorescence intensity. A tracer saturated collagen gel was visualized 
during each diffusion experiment to compensate for potential pho-
tobleaching of tracer and to normalize the gradient profiles for further 
processing. Image sequences were processed in ImageJ. Diffusion rates 
were obtained by least squares fitting an analytical solution of Fick’s 
second diffusion law to the resulting averaged axial intensity profiles 
in MATLAB (MathWorks)50.
Gene targeting
To silence Sox9, Cpt1a, Atg5, Foxo1 or Foxo3a, we transduced cells in the 
presence of 8 μg ml−1 polybrene (Sigma-Aldrich), with a lentivirus carry-
ing a shRNA against SOX9[51] (Addgene plasmid repository no. 40645; 
multiplicity of infection (MOI) 50), CPT1a (MISSION, Sigma-Aldrich; 
MOI 25) or ATG5 (MISSION, Sigma-Aldrich; MOI 25), or concomitantly 
with shRNAs against Foxo1 and Foxo3a (MISSION, Sigma-Aldrich; each 
at MOI 25). To overexpress SOX9 we transduced cells, in the presence of 
8 μg ml−1 polybrene, with a lentivirus carrying a SOX9-overexpression 
plasmid[51] (Addgene plasmid repository no. 36979; MOI 150). A non-
sense scrambled (Scr) shRNA sequence or empty vector was used as 
a negative control. After 24 h, virus-containing medium was changed 
to normal culture medium and 48 h later, cells were used for further 
experiments. Target knockdown was confirmed by western blot.
To silence expression of Foxo genes using CRISPR–Cas9, we trans-
duced Cas9-expressing C3H10T1/2 cells (Cas9: Addgene plasmid 
repository no. 48139)52, with a lentivirus carrying doxycycline-induc-
ible sgRNAs against Foxo1 (GenBank accession number NM_019739) 
(5′-TTGTAAAGGTGTCTTCACGGGGG-3′) and Foxo3a (GenBank acces-
sion number NM_019740) (5′-CATTCTGAACGCGCATGAAGCGG-3′) 
(doxycycline-inducible plasmid: Addgene plasmid repository no. 
70183)53. Cells were cultured in the presence of doxycycline (250 ng ml−1) 
for 72 h before experiments.
Quantification of active FOXO levels
Levels of active FOXO were measured using the TransAM FKHR (FOXO1) 
DNA-binding ELISA (Active Motif) on nuclear protein extracts, and 
normalized to total nuclear protein input as measured by bicinchoninic 
acid assay (Pierce BCA Protein Assay Kit; Thermo Scientific).
Total RNA extraction and RT–qPCR analysis
Total RNA from cultured cells was extracted using the RNeasy Mini 
Kit (Qiagen). Total RNA from cortical bone (femurs of eight-week-
old mice, cleaned and flushed to remove bone marrow) and cartilage 
(growth plates dissected from the distal femur and proximal tibia 
of three-day-old pups) was extracted using TRIzol (Invitrogen) fol-
lowed by RNA clean-up using the RNeasy Mini Kit. mRNA was reverse 
transcribed using Superscript II Reverse Transcriptase (Invitrogen). 
Reverse transcription with quantitative PCR (RT–qPCR) was performed 
on the 7500 Fast Real-Time PCR System (Applied Biosystems). Spe-
cific forward and reverse oligonucleotide primers were used either 
in conjunction with SYBR Green dye (Cpt1a, Acadm, Acadl and Myod 
(also known as Myod1)) or with FAM-TAMRA conjugated probes (all 
others). The following primers and probes were used: Sox9 (GenBank 
accession number NM_011448): 5′-TCTGGAGGCTGCTGAACGA-3′ 
(forward), 5′-TCCGTTCTTCACCGACTTCCT-3′ (reverse), 5′-FA 
M-CAGCACAAGAAAGACCACCC-TAMRA-3′ (probe); Col2a1 (GenBank 
accession number NM_031163): 5′-AGAACATCACCTACCACTGTA 
AGAACA-3′ (forward), 5′-TGACGGTCTTGCCCCACTT-3′ (reverse), 
5′-FAM-CCTTGCTCATCCAGGGCTCCAATG-TAMRA-3′ (probe); Acan 
(GenBank accession number NM_001361500): 5′-GCATGAGAGA 
GGCGAATGGA-3′ (forward), 5′-CTGATCTCGTAGCGATCTTTCTTCT-3′ 
(reverse), 5′-FAM-CTGCAATTACCAGCTGCCCTTCACGT-TAMRA-3′ 
(probe); Runx2 (GenBank accession number NM_001146038): 
5′-TACCAGCCACCGAGACCAA-3′ (forward), 5′-AGAGGCTGTT 
TGACGCCATAG-3′ (reverse), 5′-FAM-CTTGTGCCCTCTGTT 
GTAAATACTGCTTGCA-TAMRA-3′ (probe); Ocn (GenBank accession 
number NM_007541): 5′-GGCCCTGAGTCTGACAAAGC-3′ (forward), 
5′-GCTCGTCACAAGCAGGGTTAA-3′ (reverse), 5′-FAM-ACAGACTCC 
GGCGCTACCTTGGAGC-TAMRA-3′ (probe); Pparg (GenBank acces-
sion number NM_001127330): 5′- CCCAATGGTTGCTGATTACAAA-3′ 
(forward), 5′-AATAATAAGGTGGAGATGCAGGTTCT-3′ (reverse), 5′-FA 
M- CTGAAGCTCCAAGAATACCAAAGTGCGATC-TAMRA-3′ (probe); 
Myod (GenBank accession number NM_010866): 5′-GCGCGAGTCCA 
GGCCAGG-3′ (forward), 5′-CGACTCTGGTGGTGCATCTGC-3′ (reverse); 
Slc2a1 (GenBank accession number NM_011400): 5′-GGGCATGTGCTT 
CCAGTATGT-3′ (forward), 5′-ACGAGGAGCACCGTGAAGAT-3′ (reverse), 
5′-FAM-CAACTGTGCGGCCCCTACGTCTTC-TAMRA-3′ (probe); Pfkfb3 
(GenBank accession number NM_001177757): Mm.PT.51.16600796 
(Integrated DNA Technologies); Ldha (GenBank accession num-
ber NM_010699): 5′-TTCATCATTCCCAACATTGTCAA-3′ (forward), 
5′-CACTGATTTTCCAAGCCACGTA-3′ (reverse), 5′-FAM-AGTCCACAC 
TGCAAGCTGCTGATCGTC-TAMRA-3′ (probe); Cpt1a (GenBank acces-
sion number NM_013495): 5′-GCCCATGTTGTACAGCTTCC-3′ (forward), 
5′-TTGGAAGTCTCCCTCCTTCA-3′ (reverse); Acadm (GenBank accession 
number NM_007382): 5′-TTTCGAAGACGTCAGAGTGC-3′ (forward), 
5′-TGCGACTGTAGGTCTGGTTC-3′ (reverse); Acadl (GenBank accession 
number NM_007381): 5′-TCTTTTCCTCGGAGCATGACA-3′ (forward), 
5′-GACCTCTCTACTCACTTCTCCAG-3′ (reverse). Expression levels were 
analysed using the 2−ΔΔCt method and were normalized for the expres-
sion of the housekeeping gene Actb.
RNA-seq, gene expression quantification and enrichment 
analysis of transcription binding motifs
In brief, total RNA was extracted from C3H10T1/2 cells seeded in six-
well plates using TRIzol. Polyadenylated RNA enrichment, reverse 
transcription and stranded library preparation were done using the 
KAPA stranded mRNA-seq kit (Roche). The first 50 bases of these 
libraries were sequenced on a HiSeq4000 (Illumina) and mapped to 
the murine genome (build mm10) using TopHat v.2.1.154. Read counts 
were processed using EdgeR v.3.20.955 to identify genes differentially 
expressed between cells that were serum-starved (1% FBS) and cells 
that were control-treated (10% FBS). The top-100 most-significantly 
upregulated genes upon serum starvation (at a 1% false discovery rate, 
differential expression in EdgeR is assessed for each gene using an exact 
test analogous to Fisher's exact test, but adapted for overdispersed 
data55) were analysed for motif enrichment using i-cisTarget26.
Single-cell RNA-seq- of mouse long bone
The single-cell RNA-seq dataset of the mouse long bone and bone mar-
row stroma was generated previously and detailed information on cell 
isolation, cell sorting, library preparation, RNA-seq and data process-
ing is provided in the original manuscript21. A set of 40 genes involved 
in FAO and 34 genes involved in glycolysis was curated from the Gene 
Ontology database (http://software.broadinstitute.org/gsea/msigdb) 
and the Kyoto Encyclopedia of Genes and Genomes (KEGG) database 
(http://www.genome.jp/kegg). Gene expression was calculated as the 
fraction of its unique molecular identifier (UMI; random barcode) count 
with respect to total UMI in the cell and then multiplied by 10,000. We 
denoted it as transcripts per 10,000 transcripts (TP10K).
ChIP–qPCR
ChIP–qPCR was performed as described56. In brief, 3 h after serum 
deprivation, C3H10T1/2 cells were fixed using 1% formaldehyde, washed 
and collected by centrifugation (1,000g for 5 min at 4 °C). The pellet 
was resuspended in RIPA buffer (50 mM Tris-HCl pH 8, 150 mM NaCl, 
2 mM EDTA, 1% Triton-X100, 0.5% sodium deoxycholate, 1% SDS and 1% 
protease inhibitors), homogenized, incubated on ice for 10 min and 
sonicated. The samples were centrifuged (16,000g for 10 min at 4 °C) 
and from the supernatant sheared chromatin was used as input (1/30), 
and on the remainder of the chromatin immunoprecipitation was 
performed with an anti-FOXO1 antibody (rabbit anti-FOXO1, Abcam, 
ab39670) or an anti-FOXO3a antibody (rabbit anti-FOXO3a, Abcam, 
ab12162). After precipitation using Pierce Protein A/G Magnetic Beads 
(Thermo Fisher Scientific), followed by RNA and protein digestion, DNA 
was purified using Agencourt AMPure XP (Beckman Coulter) accord-
ing to the manufacturer’s instructions. RT–qPCR was performed using 
SYBR GreenER qPCR SuperMix Universal (Thermo Fisher Scientific) and 
specific primers for the Sox9 promoter region (5′-TGTGGGCATATTG-
GCTTCT-3′ (forward), 5′-GGTTAAACTGGGAAGACTCATGG-3′ (reverse)).
Statistical analysis
All numerical results are reported as mean ±  s.e.m. Statistical signifi-
cance of the difference between experimental groups was analysed 
by two-tailed Student’s t-test, one-way, two-way or three-way ANOVA 
with Bonferroni post hoc test (as indicated in the figure legends and 
source data files) using the GraphPad Prism software. Differences were 
considered statistically significant for P < 0.05. In the studies performed 
in cell lines in culture, all experiments were independently repeated at 
least three times. Experiments using primary cells were performed with 
at least three biological replicates. Western blots were independently 
repeated at least twice. Mice for experiments were randomly allocated 
to groups. All numerical values used for graphs and detailed statistical 
analysis can be found in the source data files.
Reporting summary
Further information on research design is available in the Nature 
Research Reporting Summary linked to this paper.
Data availability
The bulk RNA-seq data that support the findings of this study have been 
deposited in ArrayExpress with the accession number E-MTAB-7564. 
The single-cell RNA-seq data were generated previously21 and are 
deposited in the Gene Expression Omnibus with accession number 
GSE128423. A portal for exploring the entire atlas is available at https://
portals.broadinstitute.org/single_cell/study/mouse-bone-marrow-
stroma-in-homeostasis. Source Data for Figs. 1–4 and Extended Data 
Figs. 1–8 are provided with the paper. All other data supporting the 
findings of this study are available within the paper.
Code availability
The full code used for the computational model of bone-graft healing 
is available from the authors upon request. More background informa-
tion on the development of the model can be found in our previous 
publications10,11.
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Extended Data Fig. 1 | Removal of periosteum reduces bone formation and 
callus vascularization. a, Histological characterization of the mouse bone-
autograft healing model. At the host–graft junction cartilage (safranin O+) is 
formed at PFD7. Note absence of CD31+ blood vessels in these regions. Near the 
graft centre new woven bone (bright pink on H&E staining) is deposited, 
cartilage is absent and blood vessels are abundant. By PFD14, the cartilage at 
the host–graft junction is gradually being replaced by bone, while the woven 
bone near the graft centre appears mature (representative images of four 
mice). Scale bars, 200 μm in host–graft junction images, 100 μm in graft-centre 
images, 50 μm in magnifications. b, MicroCT-based visualization and 
quantification of newly formed bone around control autografts, autografts 
from which the periosteum was removed or devitalized allografts (no living 
cells) at PFD28 (n = 3 mice). Coverage ratio represents percentage of graft 
surface covered by new bone. c, Dual-energy microCT-based visualization and 
quantification of vascularization in a 250-μm-wide region around autografts 
and allografts at PFD14 (n = 5 mice for autograft, n = 6 mice for devitalized 
allograft). d, CD31 immunohistochemical visualization and quantification of 
vascularization in a 250 μm-wide region around autografts and allografts at 
PFD14 (n = 3 mice). Scale bars, 500 μm. b, bone; c, cartilage; ft, fibrous tissue;  
g, graft; h, host; m, muscle; p, periosteum. Data are mean ± s.e.m.; one-way 
ANOVA with Bonferroni post hoc test (b), two-tailed Student’s t-test (c, d).
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Extended Data Fig. 2 | Reducing vascularization alters but does not prevent 
bone healing. a, Histological visualization and quantification of apoptotic 
cells (TUNEL+; n = 4 mice for control, n = 5 mice for filter 0.2) in the callus of 
grafts with or without a filter (0.2 μm pore size) at PFD7. Scale bars, 50 μm.  
b, Histological visualization and quantification of proliferating (BrdU+; n = 3 
mice) cells in the callus of grafts with or without a filter (0.2 μm pore size) at 
PFD7. Scale bars, 100 μm. c, MicroCT-based visualization and quantification of 
newly formed bone around control grafts or grafts surrounded by a filter 
(0.2 μm pore size) at PFD14 (n = 4 mice for control, n = 6 mice for filter 0.2). 
Coverage ratio represents percentage of graft surface covered by new bone.  
d, Cell tracing of donor periosteal cells during healing of bone grafts, derived 
from CAG-eGFP mice, with or without filter (0.2 μm pore size) at PFD14 showing 
equal contribution of donor cells to cartilage in both conditions, but reduced 
contribution of donor cells to bone near the graft ends. Arrows, GFP+ 
osteoblasts; arrowheads, GFP+ osteocytes; representative images of three 
mice. Scale bars, 50 μm. e, MicroCT-based visualization and quantification of 
newly formed bone around control grafts or grafts surrounded by a filter 
(0.2 μm pore size) at PFD28 (n = 3 mice). f, Histological analysis of autografts 
with or without a filter (0.2 μm pore size) at PFD28 showing comparable callus 
morphology and composition, although remaining cartilage islands (detail 
image) were seen when a filter was present but not in the callus of control grafts 
(representative images of three mice). Scale bars, 500 μm. Data are 
mean ± s.e.m.; two-tailed Student’s t-test.
Extended Data Fig. 3 | In silico modelling supports a role for nutritional 
stress in chondrogenic commitment. Application of a previously described 
computational model of bone repair10,11 to the bone-graft healing setup. In this 
model, the behaviour (survival, proliferation, differentiation and tissue 
formation) of skeletal progenitor cells, chondrocytes, osteoblasts and 
fibroblasts is dependent on the local supply of nutrients by blood vessels, in 
addition to the presence of growth factors, extracellular matrix and the cell 
density. a, Schematic overview (top) of the modelled region shown in green. 
The hatched area represents the graft callus. At the start of the simulation the 
modelled region was filled with loose fibrous tissue matrix, growth factors, 
stem cells, osteoblasts, fibroblasts and nutrients, representing the fracture 
haematoma. Overview of the Dirichlet boundary conditions (bottom) showing 
the starting points of blood vessels and the sites of release of cells and growth 
factors (and nutrients for the condition with filter) during the healing process. 
b, Application of the model to the normal bone graft (that is, blood vessels can 
come from the muscle side). Heat map-based visualization of blood vessel, 
nutrient, cartilage and bone distribution in the modelled region at different 
time points shows that the model correctly predicts the spatiotemporal 
progression of the bone-healing process. Nutrients and tissue fractions are 
expressed on a non-dimensional scale ranging from 0 (absence) to 1 
(saturation). c, d, Application of the model to bone-graft healing in the 
presence of a filter placed in between graft and muscle (that is, blood vessels 
cannot come from the muscle side) with visual representation (c) and 
quantification (d) of the different tissue fractions in the modelled region. 
Quantification was performed only in the left rectangle of the modelled region, 
as indicated by the hatched area in a, representing the graft callus. The amount 
of nutrients that can pass through the filter (the boundary condition (BC)) was 
varied between 100% (the maximum amount that can be supplied by the 
vasculature, applied to the whole filter length, resulting in similar nutrient 
distributions as in the control) and 0%. When nutrient supply through the filter 
is set at 20–40%, the model correctly recapitulates the chondrogenic switch in 
the central region of the graft as observed in vivo. When nutrient supply 
through the filter was >40%, the cells in the central graft region differentiated 
directly into osteoblasts, and a supply of nutrients <20% induced massive cell 
death and completely prevented tissue formation and graft healing. e, Visual 
representation of the effect of additional growth factor (gf) diffusion and/or 
progenitor cell (prog) migration from the filter side on cartilage and bone 
fractions at day 14. The control situation (no filter) is shown on the top and the 
filter situation with a boundary condition for nutrients of 40% is shown on the 
bottom. No large effect of these additional boundary conditions on the healing 
response was observed.
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Extended Data Fig. 4 | See next page for caption.
Extended Data Fig. 4 | Skeletal progenitors resist nutritional stress via 
induction of SOX9. a, Immunoblot detection of nuclear SOX9 in C3H10T1/2 
cells and periosteal cells exposed for 24 h to control or CND medium, with 
lamin A/C as loading control (n = 2 independent experiments). b, mRNA levels 
of Sox9 and Col2a1 in periosteal cells exposed for the indicated times to control 
or CND medium (relative to control; n = 3 biologically independent samples).  
c, mRNA levels of runt-related transcription factor 2 (Runx2; osteogenic 
lineage), peroxisome proliferator-activated receptor γ (Pparg; adipogenic 
lineage) and Myod (myogenic lineage) in periosteal cells exposed for 48 h to 
control or CND medium (relative to control; n = 3 biologically independent 
samples). d, mRNA levels of Sox9 in C3H10T1/2 cells exposed for the indicated 
times to control or SD medium (relative to control, n = 3 independent 
experiments). e, Immunoblot detection of total SOX9 in C3H10T1/2 cells 
exposed for different durations to control or SD medium, with β-actin as 
loading control (n = 2 independent experiments). f, Immunoblot detection of 
nuclear and cytoplasmic SOX9 in C3H10T1/2 cells exposed for 6 h to control or 
SD medium, with lamin A/C or β-actin as loading control (n = 2 independent 
experiments). g, Immunoblot detection of SOX9 in total cell protein extracts of 
C3H10T1/2 cells exposed for 6 h to control medium, SD medium or SD medium 
supplemented with different concentrations of the transcription inhibitor 
actinomycin D (Act. D) or the translation inhibitor cycloheximide (CHX). 
Detection of β-actin was used as loading control (n = 2 independent 
experiments). h, mRNA levels of Runx2, Pparg and Myod in C3H10T1/2 cells 
exposed for the indicated times to control or SD medium (relative to control, 
n = 3 independent experiments). i, Immunoblot detection of nuclear SOX9 in 
periosteal cells exposed for 24 h to control or SD medium with lamin A/C as 
loading control (n = 3 biologically independent samples). j, Osteogenic 
differentiation of periosteal cells in control or SD medium, assessed by 
visualization of mineral deposits (alizarin red staining) and quantification of 
Ocn mRNA levels (relative to Actb, n = 3 biologically independent samples).  
k, Immunoblot detection of SOX9 in total cell protein extracts of C3H10T1/2 
cells (in control or SD medium), periosteal cells and growth plate-derived 
chondrocytes transduced with shSox9 or shScr, with β-actin as loading control. 
A longer exposure time was used for SOX9 detection in C3H10T1/2 cells and 
periosteal cells compared with chondrocytes in order to visualize any 
remaining protein in the shSOX9 conditions (n = 2 independent experiments 
for C3H10T1/2 cells, n = 3 biologically independent samples for periosteal cells, 
growth plate-derived chondrocytes). l, Quantification of cell viability of 
C3H10T1/2 cells, periosteal cells and growth plate-derived chondrocytes 
transduced with shSox9 or shSCR, after 72 h of exposure to control, SD or CND 
medium (n = 3 independent experiments for C3H10T1/2 cells, n = 3 biologically 
independent samples for periosteal cells, growth plate-derived chondrocytes). 
Data are mean ± s.e.m.; two-way ANOVA with Bonferroni post hoc test (b, d, h, l),  
two-tailed Student’s t-test (c, j). For gel source data, see Supplementary Fig. 1.
Article
Extended Data Fig. 5 | See next page for caption.
Extended Data Fig. 5 | Reduced lipid availability favours chondrogenesis 
over osteogenesis. a–c, Immunoblot detection of total SOX9 in C3H10T1/2 
cells exposed for 6 h to control medium, SD medium or SD medium 
supplemented with increasing concentrations of palmitate (a), VLDL (b) or 
PUFA (c). Detection of β-actin was used as loading control. EtOH was used as a 
vehicle control in a and c (n = 2 independent experiments). d, Histological 
visualization (by immunofluorescence for COL2) of chondrogenic 
differentiation of periosteal cells in pellet cultures in control, SD or LRS 
medium supplemented with vehicle (EtOH), oleate or PUFA (representative 
images of n = 2 independent experiments). Scale bars, 100 μm. e, Osteogenic 
differentiation of periosteal cells in control, SD or LRS medium, assessed by 
visualization of mineral deposits (alizarin red staining) and quantification of 
Ocn mRNA levels (relative to Actb, n = 3 biologically independent samples).  
f, Flow cytometric detection and quantification of the percentage of SOX9high 
cells and total SOX9 levels in C3H10T1/2 cells, periosteal cells and skeletal stem 
cells exposed for 24 h to control, SD or LRS medium (n = 4 independent 
experiments for C3H10T1/2 cells, n = 4 biologically independent samples for 
periosteal cells, skeletal stem cells). Gating for SOX9high cells was set to have 
approximately 10% SOX9high cells in control conditions in each cell type.  
g, h, Flow cytometric quantification of cell cycle (g) and apoptosis (h) in 
SOX9low and SOX9high subpopulations of C3H10T1/2 cells, periosteal cells and 
skeletal stem cells exposed for 24 h to control, SD or LRS medium (n = 3 
independent experiments for C3H10T1/2 cells, n = 3 biologically independent 
samples for periosteal cells, skeletal stem cells). i, Histological visualization 
and quantification of early chondrogenic (SOX9+) and osteogenic (Col1a1-
DsRed+) cells in metatarsals cultured for one week in control medium, SD 
medium or SD medium supplemented with PUFA or vehicle (EtOH) (n = 6 
biologically independent samples for control, SD and SD + vehicle, n = 7 
biologically independent samples for SD + PUFA). Scale bars, 50 μm.  
j, Histological visualization of mineralization by Von Kossa staining in 
metatarsals cultured for one week in control medium, SD medium or SD 
medium supplemented with vehicle or PUFA (representative images of n = 6 
biologically independent samples for control, SD and SD + vehicle, n = 7 
biologically independent samples for SD + PUFA). Scale bars, 100 μm.  
k, Histological visualization (safranin O staining) and quantification of 
cartilage and woven bone in the callus at PFD7 of mice treated daily with free 
fatty acids (FFA; 20 μl corn oil) or sham injection (saline) at the fracture site 
(n = 5 mice). Scale bars, 500 μm. l, Flow cytometric quantification of total SOX9 
levels in C3H10T1/2 cells or skeletal stem cells exposed for 24 h to control, SD or 
LRS medium supplemented with 100 μM GW9508 or vehicle (DMSO) (n = 3 
independent experiments for C3H10T1/2 cells, n = 3 biologically independent 
samples for skeletal stem cells). m, Visualization and quantification of 
diffusion of a fluorescent fatty acid (FL-C16) and fluorescent glucose (2-NBDG) 
in collagen gels seeded with periosteal cells (5 × 106 per ml) (n = 3 biologically 
independent samples for FL-C16, n = 5 biologically independent samples for 
2-NBDG). Scale bars, 500 μm. n, o, Visualization of alcian blue staining (n) and 
visualization and quantification of Sox9 expression (o) in micromass co-
cultures of periosteal cells from Sox9-GFP mice and sorted cell populations 
from skeletal muscle of CAG-DsRed mice, after nine days in chondrogenic SD 
medium (n = 4 biologically independent samples). Addition of oleate was used 
as positive control. Scale bars, 100 μm. EC, endothelial cell, MΦ, macrophage. 
Data are mean ± s.e.m.; one-way ANOVA (e, f, i, o), two-way ANOVA (h, l) or 
three-way ANOVA (g) with Bonferroni post hoc test, two-tailed Student’s t-test 
(k, m). For gel source data, see Supplementary Fig. 1.
Article
Extended Data Fig. 6 | See next page for caption.
Extended Data Fig. 6 | Chondrocytes do not depend on FAO. a, Quantification 
of glycolytic rate, oxygen consumption and palmitate oxidation in periosteal 
cells (PC, n = 5 biologically independent samples), skeletal stem cells (SSC, n = 3 
biologically independent samples), growth plate-derived chondrocytes (GCH, 
n = 3 biologically independent samples for oxygen consumption, n = 4 
biologically independent samples for glycolysis and palmitate oxidation), rib 
chondrocytes (RCH, n = 5 biologically independent samples for oxygen 
consumption, n = 4 biologically independent samples for glycolysis and 
palmitate oxidation), calvarial osteoblasts (COB, n = 5 biologically independent 
samples) and trabecular osteoblasts (TOB, n = 5 biologically independent 
samples). b, t-Distributed stochastic neighbour embedding (t-SNE) plot of 
20,896 non-haematopoietic cells (mixed bone and bone marrow fractions, 
n = 6 mice) based on single-cell RNA-seq data, annotated post hoc and coloured 
by clustering (top) or by expression (ln(TP10K)) of selected genes (bottom).  
c, Expression (row-wide Z score of ln of average TP10K; single-cell RNA-seq) of 
FAO- and glycolysis-related genes (rows) in the cells of each cluster (columns). 
d, RT–qPCR analysis of genes involved in glycolysis (Glut1 (also known as 
Slc2a1), Pfkfb3 and Ldha; n = 6 independent samples for Glut1 and Pfkfb3 in 
cartilage, n = 9 independent samples for Glut1 and Pfkfb3 in bone, n = 8 
independent samples for Ldha) and FAO (Cpt1a, Acadm and Acadl; n = 8 
independent samples) in mouse growth plate cartilage and cortical bone 
biopsies (relative to Actb). e, Analysis of adjacent histological sections of a 
growth plate and fracture callus (PFD7) of mice injected intravenously with a 
fluorescent fatty acid (Red-C12) or glucose (2-NBDG) (representative images of 
n = 3 mice). Scale bars, 100 μm in growth plate images, 50 μm in fracture callus 
images. f, Immunofluorescence analysis of a fracture callus (PFD7) of a mouse 
injected intravenously with a fluorescent fatty acid (Red-C12) and stained for 
SOX9 (left; cartilage area shown) or COL1 (right; trabecular bone area shown) 
(representative images of n = 3 mice). Scale bars, 50 μm. g, Histological 
visualization and quantification at PFD7 of CAG-DsRed+ skeletal stem cells 
(SSC), transduced with shCpt1a or shScr and transplanted at the fracture site on 
PFD0 (n = 3 mice). Dotted lines delineate cortical bone ends. h, Quantification 
of number of live and dead cells in cultures of periosteal cells, growth plate-
derived chondrocytes and calvarial osteoblasts after 48 h of exposure to 
etomoxir (n = 3 biologically independent samples). Data are mean ± s.e.m.; one-
way (a) or two-way (h) ANOVA with Bonferroni post hoc test, two-tailed 
Student’s t-test (d, g).
Article
Extended Data Fig. 7 | Changes in FAO and autophagy after lipid deprivation. 
a, Oxidation of extracellularly added palmitate by periosteal cells in control 
medium or at different times in LRS medium (n = 4 biologically independent 
samples). b, Quantification of FAO-linked OCR in periosteal cells in control 
medium or at different times in LRS medium (n = 4 biologically independent 
samples). c, Confocal microscopy of periosteal cells labelled with Red-C12 
(fluorescent fatty acid, red) and stained with MitoTracker (mitochondria, 
green) and DPH (lipid droplets, blue) shows increased colocalization (as 
quantified by Pearson’s correlation coefficient) of MitoTracker and Red-C12 
after exposure of cells for 6 h to SD medium (n = 4 biologically independent 
samples). Scale bars, 20 μm. d, Immunoblot detection of LC3 in total cell 
protein extracts of C3H10T1/2 cells and periosteal cells exposed for different 
times to control or SD medium, with β-actin as loading control. Note increased 
conversion of LC3-I to LC3-II at early time points, indicative of activation of 
autophagy (n = 2 independent experiments). e, f, Confocal microscopy of 
C3H10T1/2 cells (e; n = 3 independent experiments) or periosteal cells (f; n = 3 
biologically independent samples), expressing an RFP–GFP–LC3 tandem 
construct, shows activation of autophagy with time upon serum deprivation, 
evidenced by increased total number of LC3 puncta per cell and higher 
percentage of RFP+GFP− puncta. Scale bars, 20 μm. g, Confocal microscopy-
based visualization (top) and quantification (bottom) of C3H10T1/2 cells, 
stained with the neutral lipid dye DPH to reveal lipid-droplet dynamics at 
different time points after SD. Cells were transduced with shAtg5 to inhibit 
autophagy or shScr as a control (n = 6 independent experiments). Scale bars, 
20 μm. h, Quantification of FAO-linked OCR in periosteal cells in control 
medium or at different times after serum deprivation, treated with 10 μM 
chloroquine (CQ) or vehicle (n = 3 biologically independent samples).  
i, Quantification of cell viability of C3H10T1/2 cells and periosteal cells after 
72 h of exposure to control or SD medium in the presence or absence of 50 μM 
(C3H10T1/2 cells) or 10 μM (periosteal cells) CQ (n = 3 independent 
experiments for C3H10T1/2 cells, n = 3 biologically independent samples for 
periosteal cells). j, Immunoblot detection of total SOX9 in C3H10T1/2 cells and 
nuclear SOX9 in periosteal cells exposed for 6 h (C3H10T1/2 cells) or 24 h 
(periosteal cells) to control medium (with DMSO as vehicle control) or medium 
supplemented with 100 μM etomoxir (Eto), with β-actin or lamin A/C as loading 
control (n = 2 independent experiments for C3H10T1/2 cells, n = 3 biologically 
independent samples for periosteal cells). k, Cell morphology of growth plate-
derived chondrocytes transduced with shSox9 or shScr (representative images 
of six biologically independent samples). Scale bar, 100 μM. l, RT–qPCR 
analysis of genes involved in chondrogenesis (Sox9, Col2a1 and Acan) and FAO 
(Cpt1a, Acadm and Acadl) in growth plate-derived chondrocytes transduced 
with shSox9 or shScr (relative to shScr, n = 6 biologically independent samples). 
Data are mean ± s.e.m.; one-way ANOVA (a, b, e, f) or two-way ANOVA (g–i) with 
Bonferroni post hoc test, two-tailed Student’s t-test (c, l). For gel source data, 
see Supplementary Fig. 1.
Extended Data Fig. 8 | Lipids regulate SOX9 through FOXO signalling. a, Heat 
map showing differential expression of cartilage-related genes in C3H10T1/2 
cells exposed for different times to SD versus control medium, as determined 
by RNA-seq (n = 3 replicates). b, Volcano plot showing significantly enriched 
and depleted mRNAs in C3H10T1/2 cells exposed for 3 or 6 h to SD versus 
control medium, as determined by RNA-seq (n = 3 replicates). c, Top 10 most 
significantly enriched transcription factor motifs with normalized enrichment 
scores (NES) in C3H10T1/2 cells exposed for 3 h (left) or 6 h (right) to SD versus 
control medium, as determined by i-cisTarget analysis on the 100 most-
significantly increased mRNAs (n = 3 replicates). Motif shown on top is the 
Hmga1 motif for 3 h and the Atf4 motif for 6 h. d, Confocal microscopy of 
C3H10T1/2 cells stained for FOXO1 after exposure of cells for 3 h to SD or LRS 
medium in the presence of vehicle (EtOH), oleate (60 μM) or PUFA 
(representative images of two independent experiments). Scale bars, 20 μm.  
e, Nuclear FOXO activity in C3H10T1/2 cells exposed for 3 h to control, SD or 
LRS medium (n = 5 independent experiments). f, Nuclear FOXO activity in 
skeletal stem cells exposed for 3 h to control medium, LRS medium or LRS 
medium supplemented with PUFA (n = 3 biologically independent samples). 
EtOH was used as vehicle control. g, Occupancy of FOXO1 at the Sox9 promoter 
of Cas9-expressing C3H10T1/2 cells transduced with sgFoxo1, sgFoxo3a or 
sgScr, exposed for 3 h to control or SD medium, as determined by ChIP–qPCR 
(n = 3 independent experiments). h, Flow cytometric quantification of total 
SOX9 levels in C3H10T1/2 cells (n = 4 independent experiments for control and 
serum deprivation, n = 3 independent experiments for LRS) and skeletal stem 
cells (n = 3 biologically independent samples) exposed for 24 h to control, SD or 
LRS medium supplemented with 1 μM AS1842856 or vehicle (DMSO). i, 
Immunoblot detection of total SOX9 in Cas9-expressing C3H10T1/2 cells 
transduced with inducible sgFoxo1 and sgFoxo3a (sgFoxo1/3a) or with sgScr, 
exposed for 6 h to control, SD or LRS medium in the presence or absence of 
doxycycline (dox; 250 ng ml−1), with β-actin as loading control (n = 2 
independent experiments). j, Flow cytometric quantification of total SOX9 
levels in skeletal stem cells transduced with shFoxo1 and shFoxo3a (shFoxo1/3a) 
or with shScr, exposed for 24 h to control, SD or LRS medium (n = 5 biologically 
independent samples). k, Histological visualization and quantification of 
FOXO3a-expressing cells in the fracture callus at PFD7 of mice treated daily 
with GW9508 (10 nmol) or vehicle (0.2% DMSO in saline) at the fracture site 
(n = 5 mice). Scale bars, 500 μm. Dotted lines delineate cortical bone ends.  
l, Histological visualization and quantification in the fracture callus at PFD7 of 
CAG–DsRed+ skeletal stem cells (SSC), transduced with shFoxo1/3a or shScr and 
transplanted at the fracture site on PFD0 (n = 5 mice). Dotted lines delineate 
cortical bone ends. Data are mean ± s.e.m.; one-way ANOVA (e, f), two-way 
ANOVA (g, h, j) with Bonferroni post hoc test, two-tailed Student’s t-test (k, l). 
For gel source data, see Supplementary Fig. 1.
Article
Extended Data Fig. 9 | Flow cytometry gating for cell sorting. a, Contour 
plots showing the gating strategy for the identification and isolation of skeletal 
stem cells from long bones of newborn mice. b, Contour plots showing the 
gating strategy for the identification and isolation of macrophages, 
endothelial cells and pericytes from skeletal muscle of adult mice.
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Statistics
For all statistical analyses, confirm that the following items are present in the figure legend, table legend, main text, or Methods section.
n/a Confirmed
The exact sample size (n) for each experimental group/condition, given as a discrete number and unit of measurement
A statement on whether measurements were taken from distinct samples or whether the same sample was measured repeatedly
The statistical test(s) used AND whether they are one- or two-sided 
Only common tests should be described solely by name; describe more complex techniques in the Methods section.
A description of all covariates tested
A description of any assumptions or corrections, such as tests of normality and adjustment for multiple comparisons
A full description of the statistical parameters including central tendency (e.g. means) or other basic estimates (e.g. regression coefficient) 
AND variation (e.g. standard deviation) or associated estimates of uncertainty (e.g. confidence intervals)
For null hypothesis testing, the test statistic (e.g. F, t, r) with confidence intervals, effect sizes, degrees of freedom and P value noted 
Give P values as exact values whenever suitable.
For Bayesian analysis, information on the choice of priors and Markov chain Monte Carlo settings
For hierarchical and complex designs, identification of the appropriate level for tests and full reporting of outcomes
Estimates of effect sizes (e.g. Cohen's d, Pearson's r), indicating how they were calculated
Our web collection on statistics for biologists contains articles on many of the points above.
Software and code
Policy information about availability of computer code
Data collection qRT-PCR: StepOne Real-Time PCR software 2.3 
Flow cytometry: BD FACSDiva 8.0 
Seahorse flux analyzer: XF Reader 1.8.1.1 
scintillation counting: QuantaSmart TM 4.0 Perkin Elmer 
Imaging: Zeiss Zen 2.5, Zeiss AxioVision 4.9.1 
Computer Modeling: MatLab R2012a/R2013a
Data analysis CT: CT Analyzer 1.16.4.1, CT Vol 2.3.2.0, MeVisLab 2.6.2 
Flow cytometry: FlowJo 10.5.3 
Statistics: GraphPad Prism 8.1.2 
Graphs: GraphPad Prism 5.0 
Image analysis: ImageJ/FIJI 2.0.0, CellProfiler 3.1.8 
Image preparation: Photoshop CS5 
RNAseq/scRNAseq analysis: TopHat 2.1.1, R statistical software 3.5.1, EdgeR 3.20.9, i-cisTarget
For manuscripts utilizing custom algorithms or software that are central to the research but not yet described in published literature, software must be made available to editors/reviewers. 
We strongly encourage code deposition in a community repository (e.g. GitHub). See the Nature Research guidelines for submitting code & software for further information.
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Data
Policy information about availability of data
All manuscripts must include a data availability statement. This statement should provide the following information, where applicable: 
- Accession codes, unique identifiers, or web links for publicly available datasets 
- A list of figures that have associated raw data 
- A description of any restrictions on data availability
The bulk mRNA sequencing data that support the findings of this study have been deposited in ArrayExpress with the accession number E-MTAB-7564 (http://
www.ebi.ac.uk/arrayexpress/experiments/E-MTAB-7564). The single cell RNA sequencing data were generated previously and are deposited in GEO (GSE128423, 
https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE128423). A portal for exploring the entire atlas is available (https://portals.broadinstitute.org/single_cell/
study/mouse-bone-marrow-stroma-in-homeostasis). All other data supporting the findings of this study are available within the paper. 
 
Figures 2,4 and Extended Data Figures 4,5,7,8 have associated raw data, provided as Supplemental Information Figure 1 for uncropped blot pictures
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For a reference copy of the document with all sections, see nature.com/documents/nr-reporting-summary-flat.pdf
Life sciences study design
All studies must disclose on these points even when the disclosure is negative.
Sample size No statistical tests were used to pre-determine sample size, but sample size was chosen based on previous experiments and comparable 
studies in literature. Sample size for each experiment is indicated in the legend. 
Data exclusions No data was excluded.
Replication In the studies performed in cell lines in culture, all experiments were independently repeated at least three times. Experiments using primary 
cells were performed with at least three biological replicates. Western Blots were independently repeated at least twice. All attempts at 
replication were successful
Randomization Mice for experiments were randomly allocated to groups.
Blinding Blinding was widely used in the study. Data collection and analysis, such as immunostaining, qRT-PCR, and Western blot were frequently 
performed by participants other than the experiment designer. During these data collection and analysis steps, all participants were routinely 
blinded to group allocation.
Reporting for specific materials, systems and methods
We require information from authors about some types of materials, experimental systems and methods used in many studies. Here, indicate whether each material, 
system or method listed is relevant to your study. If you are not sure if a list item applies to your research, read the appropriate section before selecting a response. 
Materials & experimental systems
n/a Involved in the study
Antibodies
Eukaryotic cell lines
Palaeontology
Animals and other organisms
Human research participants
Clinical data
Methods
n/a Involved in the study
ChIP-seq
Flow cytometry
MRI-based neuroimaging
Antibodies
Antibodies used Antibodies for flow cytometry: 
PE/Cy7 anti-mouse CD45: BioLegend, #103114, clone 30-F11, lot B243728, 1/200 dilution 
PE/Cy7 anti-mouse TER-119: BioLegend, #116222, clone TER-119, lot B251241, 1/200 dilution 
APC anti-mouse CD202b (Tie-2, CD202): BioLegend, #124010, clone TEK4, lot B231548, 1/200 dilution 
PE anti-mouse CD202b (Tie-2, CD202): BioLegend, #124008, clone TEK4, lot B207408, 1/200 dilution 
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APC anti-mouse CD105: BioLegend, #120414, clone MJ7/18, lot B204640, 1/200 dilution 
Pacific Blue anti-mouse CD105: BioLegend, #120412, clone MJ7/18, lot B245562, 1/200 dilution 
APC anti-mouse CD90.2: BioLegend, #105312, clone 30-H12, lot B208842, 1/200 dilution 
FITC anti-mouse Ly-51 (6C3): BioLegend, #108305, clone 6C3, lot B218198, 1/200 dilution 
PerCP-eFluor 710 anti-mouse CD200: eBioscience, #46-5200-82, clone OX90, lot 4298111, 1/200 dilution 
Biotin anti-mouse CD51: BD Pharmingen, #551380, clone RMV-7, lot 3301919, 1/200 dilution 
PE anti-Ki67: BD Pharmingen, #556027, clone B56, lot 5113743, 1/10 dilution 
PE anti-active Caspase 3: BD Pharmingen, #550821, clone C92-605, lot 25660, 1/100 dilution 
AlexaFluor 647 anti-SOX9: Cell Signaling Technology, #71273, clone D8G8H, lot 1, 1/100 dilution 
APC anti-mouse CD146: BioLegend, #134712, clone ME-9F1, lot B268897, 1/200 dilution 
Pacific Blue anti-mouse F4/80: BioLegend, #123124, clone BM8, lot B217178, 1/200 dilution 
PerCP/Cy5.5 anti-mouse CD31: BioLegend, #102522, clone MEC13.3, lot 4052815, 1/200 dilution 
 
Primary antibodies for immunohistochemical analysis: 
BrdU: Bio-Rad, #OBT0030, clone BU 1/75-ICR1, Rat, lot 0512, 1/500 dilution 
CD31: BD Biosciences, 550274, clone MEC 13.3, Rat, lot 7292994, 1/50 dilution 
type I collagen: Novus Biologicals, clone NB600-408, polyclonal, rabbit, lot 40267, 1/100 dilution 
type II collagen: Merck, MAB8887, monoclonal, mouse, clone 6B3, lot 2933390, 1/200 dilution 
SOX9: Novus Biologicals, NBP1-85551, polyclonal, rabbit, lot B113838, 1/200 dilution 
CPT1a: Cell Signaling Technology, #12252, clone D3B3, rabbit, lot 1, 1/50 dilution 
GLUT1: Cell Signaling Technology, #12939, clone D3J3A, rabbit, lot 1, 1/100 dilution 
FoxO3a: Cell Signaling Technology, #2497, clone 75D8, rabbit, lot 5, 1/100 dilution 
 
Secondary antibodies for immunohistochemical analysis: 
Biotin anti-mouse: Dako, #E0433, goat, lot 00062137 
Fluorescein anti-mouse: Sigma-Aldrich, #F0257, goat, lot SLBV6490 
Biotin anti-rat: BD Biosciences, #559286, goat, lot 6321784 
Biotin anti-rat: Dako, #E0468, rabbit, lot 00043220 
Biotin anti-rabbit: Dako, #E0432, goat, lot 20027287 
Cy3 anti-rabbit: Jackson ImmunoResearch, #111-165-003, goat, lot 84241 
AlexaFluor 546 anti-rabbit: Invitrogen, #A-11010, goat, lot 1904467 
AlexaFluor 488 anti-rabbit: Invitrogen; #A-11034, goat, lot 1937195 
 
Primary antibodies for immunocytochemical analysis: 
FoxO1: Cell Signaling Technology, #2880, clone C29H4, rabbit, lot 11, 1/100 dilution 
FoxO3a: Cell Signaling Technology, #2497, clone 75D8, rabbit, lot 5, 1/100 dilution 
 
Secondary antibodies for immunocytochemical analysis: 
AlexaFluor 488 anti-rabbit: Invitrogen; #A-11034, goat, lot 1937195 
 
Primary antibodies for Western Blot: 
SOX9: Novus Biologicals, NBP1-85551, polyclonal, rabbit, lot B113838, 1/2000 dilution 
FoxO1: Cell Signaling Technology, #2880, clone C29H4, rabbit, lot 11, 1/1000 dilution 
FoxO3a: Cell Signaling Technology, #2497, clone 75D8, rabbit, lot 5, 1/1000 dilution 
LC3B: Cell Signaling Technology, #3868, clone D11, rabbit, lot 11, 1/500 dilution 
β-actin: Sigma-Aldrich, #A5441, clone AC-15, mouse, lot 026M, 1/10000 dilution 
Lamin A/C: Santa Cruz Biotechnology, #sc-376248, clone E-1, mouse, lot C1412, 1/5000 dilution 
 
Secondary antibodies for Western blot analysis: 
HRP anti-mouse: Dako, #P0161, rabbit, lot 00095192 
HRP anti-rabbit: Dako, #P0448, goat, lot 00094764 
 
Primary antibodies for ChIP-qPCR: 
FoxO1: Abcam, #ab39670, rabbit, lot GR3192176-1, 1/250 dilution 
FoxO3a: Abcam, #ab12162, rabbit, lot GR226465-14, 1/250 dilution
Validation All antibodies were obtained from indicated commercial vendors with ensured quality. In addition, all the antibodies have been 
used in multiple experiments to detect intended proteins in control samples with expected molecular weight to validate their 
effectiveness in our study 
 
Antibodies for flow cytometry: 
 
PE/Cy7 anti-mouse CD45: BioLegend, #103114, clone 30-F11 
RRID: AB_312979 
Validated by the manufacturer by flow cytometry on C57BL/6 mouse splenocytes, 46 citations 
 
PE/Cy7 anti-mouse TER-119: BioLegend, #116222, clone TER-119 
RRID: AB_2281408 
Validated by the manufacturer by flow cytometry on C57BL/6 mouse bone marrow cells,  6 citations 
 
APC anti-mouse CD202b (Tie-2, CD202): BioLegend, #124010, clone TEK4 
RRID: AB_10897106 
Validated by the manufacturer by flow cytometry on bEnd.3 mouse endothelial cells, 3 citations 
 
PE anti-mouse CD202b (Tie-2, CD202): BioLegend, #124008, clone TEK4 
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RRID: AB_2287338 
Validated by the manufacturer by flow cytometry on bEnd.3 mouse endothelial cells, 5 citations 
 
APC anti-mouse CD105: BioLegend, #120414, clone MJ7/18 
RRID: AB_2277914 
Validated by the manufacturer by flow cytometry on bEnd.3 mouse endothelial cells, 5 citations 
 
Pacific Blue anti-mouse CD105: BioLegend, #120412, clone MJ7/18 
RRID: AB_209889 
Validated by the manufacturer by flow cytometry on bEnd.3 mouse endothelial cells, 2 citations 
 
APC anti-mouse CD90.2: BioLegend, #105312, clone 30-H12 
RRID: AB_313183  
Validated by the manufacturer by flow cytometry on C57BL/6 mouse thymocytes, 12 citations 
 
FITC anti-mouse Ly-51 (6C3): BioLegend, #108305, clone 6C3 
RRID: AB_313362 
Validated by the manufacturer by flow cytometry on C57BL/6 mouse bone marrow cells, 6 citations 
 
PerCP-eFluor 710 anti-mouse CD200: eBioscience, #46-5200-82, clone OX90  
RRID: AB_10598213 
Validated by the manufacturer by flow cytometry on 57BL/6 splenocytes, 1 citation 
 
Biotin anti-mouse CD51: BD Pharmingen, #551380, clone RMV-7 
RRID: AB_394174 
Validated by the manufacturer by flow cytometry on BALB/c bone marrow leukocytes, 8 citations 
 
PE anti-Ki67: BD Pharmingen, #556027, clone B56 
RRID: AB_2266296 
Validated by the manufacturer by flow cytometry on permeabilized MOLT-4 cells, 14 citations 
 
PE anti-active Caspase 3: BD Pharmingen, #550821, clone C92-605 
RRID: AB_393906 
Validated by the manufacturer by flow cytometry on camptothecin treated Jurkat cells, 3 citations 
 
AlexaFluor 647 anti-SOX9: Cell Signaling Technology, #71273, clone D8G8H 
RRID: AB_2799799 
Validated by the manufacturer by flow cytometry on HeLa cells (blue) and A-204 cells, 12 citations 
 
APC anti-mouse CD146: BioLegend, #134712, clone ME-9F1 
RRID: AB_2563088  
Validated by the manufacturer by flow cytometry on Mouse endothelial cells, 3 citations 
 
Pacific Blue anti-mouse F4/80: BioLegend, #123124, clone BM8 
RRID: AB_893475 
Validated by the manufacturer by flow cytometry on Thioglycolate-elicited Balb/c mouse peritoneal macrophages, 21 citations 
 
PerCP/Cy5.5 anti-mouse CD31: BioLegend, #102522, clone MEC13.3 
RRID: AB_2566761 
Validated by the manufacturer by flow cytometry on C57BL/6 mouse splenocytes, 11 citations 
 
Primary antibodies for immunohistochemical analysis: 
 
BrdU: Bio-Rad, #OBT0030, clone BU 1/75-ICR1, Rat 
RRID: AB_609568 
Validated by the manufacturer for immunohistochemistry on formalin-fixed paraffin-embedded tissue, 31 citations 
 
CD31: BD Biosciences, 550274, clone MEC 13.3, Rat 
RRID: AB_393571 
Validated by the manufacturer for immunohistochemistry on zinc-fixed paraffin-embedded section of U-87 MG tumor in mouse 
brain, 7 citations 
 
type I collagen: Novus Biologicals, clone NB600-408, polyclonal, rabbit 
RRID: AB_343276 
Validated by the manufacturer for immunohistochemistry on FFPE sections of mouse pancreas tissue and rat colon tissue, 28 
citations 
 
type II collagen: Merck Millipore, MAB8887, monoclonal, mouse, clone 6B3 
RRID: AB_2260779 
Validated by the manufacturer for immunohistochemistry on fetal cartilage, 30 citations 
 
SOX9: Novus Biologicals, NBP1-85551, polyclonal, rabbit 
RRID: AB_11002706 
Validated by the manufacturer for immunohistochemistry on FFPE sections of human colorectal cancer, glioma, skeletal muscle 
and small intestine, 4 citations 
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CPT1a: Cell Signaling Technology, #12252, clone D3B3, rabbit 
RRID: AB_2797857 
Validated by the manufacturer on HeLa, PANC-1 and MCF7 cells, 16 citations 
 
GLUT1: Cell Signaling Technology, #12939, clone D3J3A, rabbit 
RRID: AB_2687899 
Validated by the manufacturer on HepG2 and Huh6 cells, 9 citations 
 
FoxO3a: Cell Signaling Technology, #2497, clone 75D8, rabbit 
RRID: AB_836876 
Validated by the manufacturer on SH-SY5Y cells IGF-I or LY294002 treated, 230 citations 
 
Primary antibodies for immunocytochemical analysis: 
 
FoxO1: Cell Signaling Technology, #2880, clone C29H4, rabbit 
RRID: AB_2106495 
Validated by the manufacturer for immunofluorescent analysis in IGROV-1cells, 409 citations 
 
FoxO3a: Cell Signaling Technology, #2497, clone 75D8, rabbit 
RRID: AB_836876 
Validated by the manufacturer for immunofluorescent analysis on SH-SY5Y cells, 230 citations 
 
Primary antibodies for Western Blot: 
 
SOX9: Novus Biologicals, NBP1-85551, polyclonal, rabbit 
RRID: AB_11002706 
Validated by the manufacturer for western blot analysis mammalian HEK293T cells, mouse NIH-3t3 cells and rat NBT-II cells, 2 
citations 
 
FoxO1: Cell Signaling Technology, #2880, clone C29H4, rabbit 
RRID: AB_2106495 
Validated by the manufacturer for western blot analysis on extracts from IGROV-1 and COS-7 cells, 409 citations 
 
FoxO3a: Cell Signaling Technology, #2497, clone 75D8, rabbit 
RRID: AB_836876 
Validated by the manufacturer for western blot analysis on extracts from Jurkat and PC3 cells, 230 citations 
 
LC3B: Cell Signaling Technology, #3868, clone D11, rabbit 
RRID: AB_2137707 
Validated by the manufacturer for western blot analysis on extracts of various cell line treated with chloroquine, 31 citations 
 
β-actin: Sigma-Aldrich, #A5441, clone AC-15, mouse  
RRID: AB_476744 
Validated by the manufacturer for western blot analysis on cultured human or chicken fibroblast cell extracts, 299 citations 
 
Lamin A/C: Santa Cruz Biotechnology, #sc-376248, clone E-1, mouse 
RRID: AB_10991536 
Validated by the manufacturer for western blot analysis on cell extracts of different mouse and human cell lines, 4 citations 
 
Primary antibodies for ChIP-qPCR: 
 
FoxO1: Abcam, #ab39670, rabbit 
RRID: AB_732421 
Validated by the manufacturer for ChIP analysis on mouse T cells, 33 citations 
 
FoxO3a: Abcam, #ab12162, rabbit 
RRID: AB_298893 
Validated by the manufacturer for ChIP analysis on pig coronary artery endothelial cells, 30 citations 
 
β-actin: Sigma-Aldrich, #A5441, clone AC-15, mouse  
RRID: AB_476744 
Validated by the manufacturer for western blot analysis on cultured human or chicken fibroblast cell extracts, 299 citations 
 
Lamin A/C: Santa Cruz Biotechnology, #sc-376248, clone E-1, mouse 
RRID: AB_10991536 
Validated by the manufacturer for western blot analysis on cell extracts of different mouse and human cell lines, 4 citations 
 
Primary antibodies for ChIP-qPCR: 
FoxO1: Abcam, #ab39670, rabbit 
RRID: AB_732421 
Validated by the manufacturer for ChIP analysis on mouse T cells, 33 citations 
 
FoxO3a: Abcam, #ab12162, rabbit 
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RRID: AB_298893 
Validated by the manufacturer for ChIP analysis on pig coronary artery endothelial cells, 30 citations
Eukaryotic cell lines
Policy information about cell lines
Cell line source(s) C3H10T1/2 cells were obtained from the RIKEN Cell Bank
Authentication None of the cell lines used were authenticated
Mycoplasma contamination Cell lines were routinely tested for mycoplasma contamination and found negative
Commonly misidentified lines
(See ICLAC register)
The C3H10T1/2 cell line is not among the commonly misidentified cell lines
Animals and other organisms
Policy information about studies involving animals; ARRIVE guidelines recommended for reporting animal research
Laboratory animals Analysis was performed on 3-5 day-old mice or 8-10 week-old male and female mice. C57BL/6J mice (Janvier Labs), 129/Sv mice 
(Janvier Labs), B6.Cg-Tg(CAG-EGFP) mice (Hadjantonakis, A. K. et al., Mech. Dev., 1998), B6.Cg-Tg(Col1a1-cre/ERT2,-
DsRed)1Smkm/J mice (Ouyang, Z. et al., Bone, 2014), B6;129S4-Sox9tm1.1Tlu/J mice and B6.Cg-Tg(CAG-DsRed*MST)1Nagy/J 
mice (The Jackson Laboratory) were used in this study.  
All colonies were housed and bred in individually ventilated cages in the animal facility of the KU Leuven.
Wild animals The study did not use any wild animals
Field-collected samples The study did not include field-collected samples
Ethics oversight All animal experiments were conducted according to the regulations and with approval of the Animal Ethics Committee of the KU 
Leuven.
Note that full information on the approval of the study protocol must also be provided in the manuscript.
Flow Cytometry
Plots
Confirm that:
The axis labels state the marker and fluorochrome used (e.g. CD4-FITC).
The axis scales are clearly visible. Include numbers along axes only for bottom left plot of group (a 'group' is an analysis of identical markers).
All plots are contour plots with outliers or pseudocolor plots.
A numerical value for number of cells or percentage (with statistics) is provided.
Methodology
Sample preparation Isolation of mouse skeletal stem cells was adapted from a previously described protocol (Chan, C. K., et al., Cell, 2015). Long 
bones of 3-5 day old mice were dissected, muscle was cleared away and bones were minced using a scalpel. Bone fragments 
were then digested in α-MEM supplemented with 3mg/ml collagenase II, 4mg/ml dispase (both from Gibco) and 100U/ml DNAse 
I (Sigma) at 37°C for 45 minutes, with replacement of the digest medium every 15 minutes. Cell suspensions were passed 
through a 70μm cell strainer, washed with PBS containing 2% FBS and stained with antibodies against CD45, Ter119, Tie2, 
CD105, CD90.2, 6C3 (BioLegend), CD51 (BD Pharmingen) and CD200 (eBioscience), and with the viability dye 7-
aminoactinomycin D (BD Pharmingen). 
 
For the isolation of skeletal muscle-derived cell populations, hindlimb skeletal muscles, including quadriceps, soleus, 
gastrocnemius and tibialis anterior, were dissected from 8-week old CAG-DsRed mice, minced using a scalpel and digested in α-
MEM medium supplemented with 3mg/ml collagenase II, 4mg/ml dispase and 100U/ml DNAse I at 37°C for 60 minutes. Every 15 
minutes samples were pipetted up and down vigorously using a 10ml serological pipette to break up tissue fragments. Cell 
suspensions were passed through a 70μm nylon mesh, washed with PBS containing 2% FBS and stained with antibodies against 
CD45, Ter119, CD31, F4/80 and CD146 (BioLegend), and with 7AAD (BD Pharmingen). 
Instrument BD LSRII
Software BD FACSDiva
Cell population abundance Post-sort purity was not determined
Gating strategy Phenotypic skeletal stem cells (7AAD-CD45-Ter119-Tie2-CD51+CD105-CD90.2-6C3-CD200+) were sorted on a BD FACSAria II (BD 
7
nature research  |  reporting sum
m
ary
O
ctober 2018
Gating strategy Biosciences). Previously-defined gating strategies (Chan, C. K., et al., Cell, 2015) were followed and are given in Extended Data 
Fig. 9a) 
 
Immunophenotypically-defined macrophages (7AAD-CD45+F4/80+), endothelial cells (7AAD-CD45-Ter119-F4/80-CD31+CD146+) 
and pericytes (7AAD-CD45-Ter119-F4/80-CD31-CD146+) (Extended Data Fig. 9b) were sorted on a BD FACSAria II. Gating 
strategies are described in Extended Data Fig. 9b. 
 
Analysis of SOX9high cells: Gating for SOX9high cells was set to have approximately 10% SOX9high cells in control conditions for 
all cell types. 
Tick this box to confirm that a figure exemplifying the gating strategy is provided in the Supplementary Information.
